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Abstract.

Incorporation of chemical probes into proteins is a powerful way to
elucidate biological processes and to engineer novel function. This thesis
describes the ligation of synthetic molecules to target proteins in an
intracellular environment, and the use of semi-synthetic proteins for whole
animal studies.
In the first approach a cellular protein is genetically tagged with one
half of a split-intein. The complementary half is linked in vitro to the
synthetic probe and this fusion is delivered into cells using a transduction
peptide. Association of the intein halves in the cytosol triggers protein transsplicing, resulting in the ligation of the probe to the target protein through
a peptide bond. This process is specific and applicable to cytosolic and
integral membrane proteins. The technology should allow cellular proteins to
be elaborated with a variety of abiotic probes.
In the second approach a sequential expressed protein ligation was
used to link three fragments: a targeting protein, an affinity tag, and an
imaging moiety. Specifically, vascular endothelial growth factor (VEGF) was
ligated with a 6xHis tag and a synthetic high affinity "°Tc chelator.
Following protein semi-synthesis, the "°Tc was incorporated into the chelator
and the "-To-labeled protein was injected into mice bearing a tumor. The
semi-synthetic VEGF localized onto the vascularized tumor and allowed it to
be imaged with a Y camera. The strategy developed is modular, permitting
the use of multiple chemical moieties, purification methods, and targeting
proteins. This methodology could be used to provide insights into biological
processes in normal development and homeostasis, as well as during
pathogenic events such as cancers.

C h a p t e r 1: Introduction.

Proteins account for more then 5 0 % of the dry weight of most cells
and they are viewed as the basic machinery inside the cell. They are
involved in structural support, defense against foreign agents, acceleration of
chemical reactions (enzymatic activity), signaling, movement and the storage
and transport of substances within the cell.85 Historically, proteins have
been studied using biochemistry, a discipline that distinguishes itself by the
first act of its practitioners: converting cells into a soup. Studies of the
molecules purified from this soup serve to define the spectrum of possible
functions that proteins could carry out within the living cell. Biochemistry
remains a vibrant field but the reductionism at its heart creates limitations.
Proteins are in an unnatural environment and under such artificial
conditions, biochemists have to continually question the relevance of their in
vitro systems to the cellular environment.

"A clever engineer can make a vacuum cleaner from the wreck
of an automobile, but this does not show that cars contain
vacuum cleaners." Green."''5

Geography, movement and chemistry are what provide proteins with
their extraordinary capability to regulate processes in living cells, such that
only in vivo experiments can determine where, within the spectrum of
possible functions, the actual biological functions of proteins reside. Thus,
manipulating proteins in vivo, in the context of relevant physiochemical
conditions, is a necessary approach to complement biochemistry.
Classical genetics with techniques such as mutagenesis, over-expression,
knock-out, conditional alleles and others,66 has proven to be a powerful tool
for the study of proteins inside cells. Recently, these approaches have been
complemented by the discovery of fluorescent proteins.

Green Fluorescent Proteins.

The green fluorescent protein, isolated from Aequorea victoria, is a |3barrel-shaped protein that contains an amino acid triplet (Ser-Tyr-Gly) which
undergoes a chemical rearrangement to form a fluorophore.69 GFP is most
celebrated for its ability to act as a genetic fluorescent marker, being directly
visible in the living cell and requiring no fixation, substrates or coenzymes.137 This characteristic has allowed for visualizing the location and
trafficking of proteins in vivo,1311 labeling of many sub-cellular structures120
and discovery of genes whose products have a specific intracellular location.63
Because of this success, both random and rational mutagenesis have been

used

to create G F P

variants with

new

colors, improved

folding, varied

extinction coefficients and quantum yields137 which, together with orthologues
fluorescent proteins such as the sea coral protein DsRed,11 98 have increased
the breadth of genetic fluorescent markers.
New GFPs can now report on the chemical environment of a protein
thanks to their engineered sensitivity to acidity,82 89 or concentration of ions
such as Cl,73 Ca2*101 and Zn2*.10 Importantly, the availability of fluorescent
proteins with diverse colors permits the study of protein-protein interactions
through the use of fluorescence resonance energy transfer (FRET).94 101
One of the most recent development is a fluorescent protein whose
spectral properties change with time. The "fluorescent timer" protein was
generated by random mutagenesis of the red fluorescent protein DsRed.130
This protein initially produces a green-emitting fluorophore (similar to that of
GFP), which over time undergoes an oxygen-dependent autocatalytic reaction
to create a red-emitting fluorophore. The rate of color conversion is
independent of protein concentration and can be used to trace timedependent activation and down-regulation of the promoters of target
proteins.130
Although powerful, there are limitations to the use of GFP-fusion
reporters. These include the potential perturbation to the protein of interest
(due to GFPs' size of 238 amino acids), significant delay between protein

synthesis and the development of fluorescence (1 hour), limited points of
attachment, a complex photoisomerization and a small spectral range.137 The
introduction of unnatural moieties into proteins in vivo could overcome some
of these limitations and open the possibility of exploiting the orthogonality
and selectivity that chemistry has to offer. A unique probe on a protein of
interest allows it to be easily identified from a multitude of similar species,
and permits specific reactions between proteins to take place.

Chemical modification of proteins in vivo.

Chemical modification of proteins in living cells originally involved the
non-specific modification of membrane proteins with fluorescent molecules
that were covalently attached to these proteins through their side chain
amino or sulfhydryl groups. Initially such experiments were performed to
determine what parts of the membrane proteins were extra-cellular,40 but
later they permitted the study of protein diffusion constants in the plasma
membrane using fluorescent recovery after photo-bleaching (FRAP).6

Selective Pressure Incorporation.
More recently, an in vivo method termed selective pressure
incorporation18 was developed to exploit the promiscuity of wild-type bacterial
synthetases. Inducing expression of a recombinant protein in an auxotrophic

strain grown in minimal media with an unnatural amino acid analog, results
in the production of the protein containing this moiety. In general this
method is simple to carry out, and can provide large quantities of
engineered proteins. However, major limitations include the replacement of
all sites corresponding to a particular natural amino acid throughout the
protein, the variation in the extent of incorporation of the natural and
unnatural amino acid, the toxicity of some analogues and the use of only
close structural analogs of the common amino acids. Moreover, to date it
has been applicable only to bacteria.

Unnatural Amino Acid Incorporation Through Nonsense Suppression.

Many of the limitations of selective pressure incorporation were bypassed with the creation of unnatural amino acid incorporation through
nonsense suppression.106 This technique uses a suppressor transfer RNA,
chemically acylated with an unnatural amino acid, that is inserted into
proteins in response to an amber stop codon. This new technology was
introduced into an in vivo setting using Xenopus oocytes for protein
synthesis107 (Figure 1.1).
Nonsense suppression methodology has permitted in vitro and in some
cases, in vivo analysis of structure-function relationships,33 41 incorporation of
biophysical probes,32 78 incorporation of photo-reactive side chains and

"unnatural arr..r.o£tid
chonucaltv apperded
O V n H w a inputs- no"

Figure 1.1. General outline for the incorporation of unnatural amino
acids through nonsense suppression into proteins in vivo. ® The gene
of the protein is cloned with a "stop" codon at the site of interest.
© A tRNA with the appropriate anti-codon and unnatural amino
acid (*) is synthesized. ® Both are co-injected into a cell, most
commonly an oocyte. © The cell produces the protein with the
unnatural amino acid incorporated, and in the case of ion channels,
the protein is transported to the cell surface © where it can be
studied by electrophysiology.

backbone mutations.34 83 Almost 100 unnatural amino acids have been
integrated into proteins, but the technique remains challenging. Non-sense
suppression requires stoichiometric amounts of the amino acylated tRNA
(which is difficult to synthesize), the suppression efficiency is imperfect, the
yields are poor and the in vivo system used has to be amicable to the
methodology (which requires injection of both the tRNA and mRNA).42
T h e latter draw-back has impeded the study of a protein within its natural

environment (e.g. a mammalian protein in mammalian cells).

However, in a

monumental achievement, the Schultz group has made progress towards
overcoming this limitation, by expanding the genetic code of Escherichia coli
(E. coli).145 Three additional and orthogonal components for the protein
biosynthetic machinery were incorporated into the bacteria: a novel tRNAcodon pair, an aminoacyl-tRNA synthetase, and an amino acid. This new
set of components did not cross talk with the natural machinery of E. coli,
and it had a fidelity greater then 99% when incorporating the synthetic
amino acid O-methyl-L-tyrosine into proteins in response to an amber
nonsense codon.145 Since this first report, a series of unnatural amino acids
have been incorporated into the genetic code of E. coli: O-allyl-jL-tyrosine,159
p-azido-L-phenylalanine,25 L-3-(2-naphthyl)alanine146 and p-benzoyl-L
phenylalanine.24 The latter was incorporated into the dimeric protein
glutathione S-transferase (GST) and efficient cross-linking (>50%) of the
protein subunits resulted upon irradiation of the bacteria. Such results start
to shed light on the possibilities that could emerge when increasing the
repertoire of functional groups that can be introduced in vivo. Although,
nonsense suppression has made great advances, it is still unavailable in
mammalian cells, and is restricted to the use of only two redundant stop
codons.

> * w

Figure 1.2. Structure of FlAsH-EDT2.

The strucmre highlighted in

orange attaches to proteins tagged with the tetra-cysteine motif.

FlAsH

An alternative way to attach unnatural chemical moieties onto proteins
was recently developed.65

A small membrane permeable ligand FlAsH (4', 5'-

bis(l,3,2-dithioarsolan-2-yl) fluorescein) (Figure
cysteines in the sequence

1.2) that

CysCysXxxXxxCysCys

acids except cysteine) was developed.65

The

binds

the

(where Xxx is any

four
amino

small polypeptide to which

FlAsH binds can be incorporated into proteins.
FlAsH-EDT: (1,2-ethanedithiol) is practically non-fluorescent becoming
over 50,000 times more fluorescent u p o n exchanging the E D T
the tetra-cysteine sequence.

moieties for

This polypeptide is believed to be in a (3-hairpin

conformation1 and the rigid spacing of the two arsenates in FlAsH enables it
to bind with high affinity and specificity to the motif introduced in target
proteins.

Addition of micro-molar levels of 1,2-dithiols, such as E D T , can

minimize

FlAsH

toxicity

and

nonspecific

labeling,

while

milli-molar

concentrations can strip FlAsH off the target proteins.

The small size of the

genetic tag (6-10 amino acids) and relative ease of the synthesis of FlAsH
has encouraged the synthesis of new derivatives with different properties. To
date FlAsH has been modified to have red and blue emissions, photosensitize
the polymerization of diaminobenzidine (to produce a localize precipitate
useful for electron microscopy) and be membrane impermeable.1 105 FlAsH
can also survive analysis of protein by SDS-PAGE, can serve as a protein
purification tool analogous to a His-tag1 132 and the conformational rigidity
the FlAsH-peptide adducts should make them ideal for anisotropy studies.1
Recently, another methodology to chemically modify proteins in vivo was
reported. In this strategy, covalent labeling with a small molecule is
achieved through the use of an engineered human DNA repair protein O6alkylguanine-DNA alkyltransferase (hAGT), which irreversibly transfers the
alkyl group from its substrate (O'-alkylguanine-DNA) to one of its cysteines.
The substrate specificity of hAGT was reduced, allowing the ligation of
unnatural alkyl groups onto hAGT fusion proteins.79
The appeal of all these methodologies is the ability to incorporate
non-genetic coded molecules into proteins in vivo, maximizing chemically
favorable properties and minimizing possible disruption in normal protein
behavior. A novel approach in which a synthetic molecule is ligated to a
protein (i.e. semi-synthesis) inside living cells could increase the diversity of
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chemical modifications for probing cellular proteins a n d

should

complement

methods already in existence. The bases for such an approach are protein

splicing and protein transduction domain (PTD) peptides.

Protein Splicing.

Protein splicing is an autocatalytic, post-translational process in which

an intervening sequence, the intein, is removed from a host protein, the

extein.115 The first intein was discovered in 1990 as a "spacer" within the

Saccharomyces cerevisiae vacuolar ATPase (See VMA) gene that was absent in

other VMA homologs.70 76 127 Since then, over 100 putative inteins have

been identified and cataloged in InBase, the on-line intein registry and

database (http://www.neb.com/neb/inteins.html).114 Formation of a native

peptide bond between the ligated exteins is a key distinguishing feature of

intein-mediated protein splicing. To date, only a small number of inteins

C-terminal
Splicing Region

N-terminal
Splicing Region

Endonuclease Region
N-extein

C-extein

H N C
Q S
T
Figure 1.3.

General layout of an intein.

Mini-inteins have a small

linker region instead of the endonuclease. Conserved residues are
shown below in bold. The intein splicing regions (blue boxes) form
a single domain that mediates protein splicing.
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have been experimentally s h o w n

to splice, while the majority have

been

found by homology searches of whole genome sequences (Figure 1.3).114 116
The majority of inteins are bi-functional proteins that also encode homing
endonuclease signature motifs. Homing endonucleases were originally shown
to initiate mobility (or homing) of intron genes into sites in homologous
genes by creating double-stranded breaks at the homing site.43 60 Several
inteins have demonstrated endonuclease activity and the See VMA intein
gene has been shown to be mobile in yeast.61 Biochemical analysis indicates
that splicing and endonuclease active sites reside in different regions of the
intein.71 This has been further established with the crystal structure of the
See. VMA intein, which shows separately folded sub domains (Figure 1.4).117

12

Inteins are present in unicellular organisms from all 3 phylogenetic
domains: Archaea, Eukarya and Eubacteria. The absence of inteins in
multicellular organisms may be limited by the inability of mobile intein genes
to invade germ line cells. Although the role of inteins in early evolution is
unknown, several groups have suggested that they are selfish DNA elements,
or could be involved in enzyme evolution by peptide or domain ligation and
shuffling.113 It has also been proposed that inteins could control maturation
of the protein wherein they reside,118 however this is unlikely, as splicing is
rapid under physiological conditions, and precursors cannot be isolated in
organisms that have inteins.

Figure 1.4. Crystal structure of See. V M A .

The endonuclease is

represented in red, and the intein splicing regions in blue (see also
Figure 1.3 - note, in Figure 1.3 the endonuclease is presented in
black).

13

T h e standard protein splicing mechanism was first defined using the
Psp-GBD Pol intein71 154 and was later confirmed with the See VMA
intein.2829 Protein splicing requires four nucleophilic displacements mediated
by three splice junction residues (Figure 1.5). The standard protein splicing
reaction begins when the Ser or Cys at the intein amino-terminus undergoes
an acyl rearrangement, replacing the amino-terminal splice junction peptide
bond with an CC-(thio)-ester bond (Figure 1.5 ®). In the second step, a
trans-esterification reaction occurs, moving the N-extein from the side-chain of
the first residue in the intein to the side chain of the first residue in the
C-extein, which is always a Ser, Thr or Cys. This step results in ligation of

:oon

COOH

X-»N acylshiftY^

Figure 1.5.

Asn cyclization

Standard protein splicing mechanism.

"X" represents the

oxygen or sulfur atom in Ser, Thr or Cys and the steps are
explained in the text. The succinimide ring may be hydrolyzed to
reform Asn or isoasparagine. The N-terminal extein, C-terminal
extein and the intein are shown in green, red and blue respectively.
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the exteins and formation of a branched protein intermediate (Figure 1.5 © ) .
The intein is cleaved away from this intermediate when cyclization of the
intein carboxy-terminal Asn breaks the adjacent peptide bond at the carboxyterminal splice junction (Figure 1.5 ®). In the absence of the intein, a
spontaneous rearrangement of the (X-(thio)-ester linkage between the exteins
occurs, resulting in the formation of the more stable peptide bond (Figure
1.5 ©). No cofactors or exogenous proteins are required for splicing
activity. An alternative mechanism for protein splicing has also been found
for three families of inteins that begin with Ala. In this non-canonical
pathway the C-extein nucleophile attacks the peptide bond at the N-terminal
splice junction directly.117 153
Inteins function like regular enzymes, requiring facilitating groups
positioned in three dimensional space to activate nucleophiles and
electrophilic centers. However, unlike normal enzymes they only act on a
single substrate, the precursor in which they exist. This is further
highlighted when the precursor is split and splicing occurs in trans (see
below), unequal molar ratios of fragments result in the accumulation of the
fragment in excess and not in turnover (the limiting fragment does not react
with multiple partners).49 87 99 128 152
Several groups have independently demonstrated that protein splicing
precursors can be cut into two pieces that individually have no activity, but

15

when

combined

they will non-covalently associate to give a functional intein

(Figure 1.6).87 99 128 152 However, in vitro trans-splicing often requires
denaturation and renaturation of the isolated precursor fragments.99 128 The
denaturants may be required for multiple reasons: many intein fragments are
insoluble when expressed separately,99 128 possibly due to improper folding or
exposure of hydrophobic residues in the absence of the complete intein,
alternatively, aggregation or insolubility could be due to the extein portion of
the precursor fragment.128
Protein trans-splicing is a bimolecular reaction. However, once the
intein fragments reassemble, the reaction is, in effect, a uni-molecular
reaction. Since non-allelic inteins have little sequence identity, different split
inteins only re-associate with their homologous partners and not with

HX
MX
, AW" b

-NH
E r O"
k "
C-terminal
Extein

N-terminal
Extein

"
V
Inte in

Figure 1.6. Schematic representation of protein trans-splicing.

The N-

terminal extein, C-terminal extein a n d the intein are s h o w n in green,
red a n d blue respectively.

T h e intein is fragmented and inactive, but

u p o n association activity is regained.
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heterologous partners.109

Most recently, the protein trans-splicing area has

received a considerable boost through the discovery of the naturally occurring
split Synechocystis sp. (Ssp) DnaE intein.151 The dnaE gene encodes the
catalytic subunit of the replicative DNA polymerase and is an essential gene.
The two dnaE gene fragments are over 700 kilo bases (kb) apart on opposite
strands of the Ssp. PCC6803 chromosome. Significantly, this split intein
does not require denaturants for reconstitution to initiate splicing. This
feature makes the Ssp. DnaE intein especially well suited for protein
engineering applications.

Applications of Protein Splicing.
Understanding the protein splicing mechanism has led to the design
of a number of mutant inteins which have significant utility in protein
science and in particular, peptide ligation.62 Proteins expressed in-frame and
amino-terminal to a mutated intein (Ans^Ala) that can only participate in
the first step of splicing (i.e. the N-»S acyl shift, Figure 1.5 ®), can be

cleaved by thiols via an intermolecular trans-thio-esterification reaction.27 It is
also possible to mutate an intein such that after cleavage at the carboxyterminal splice junction one obtains the protein of interest with an aminoterminal Cys.97 Importantly, the use of these engineered inteins permits the
production of large recombinant building blocks for use with native chemical
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ligation, and allows for mixing of recombinant and synthetic building blocks
in chemical protein synthesis.
Native chemical ligation is a technique that allows the chemo-selective
addition of two unprotected peptides at physiological pH, with the resulting
polypeptide containing a native backbone at the point of ligation.36 In this
technique a peptide containing a C-terminal a-thioester group reacts with a
second peptide containing an amino-terminal cysteine. Thiol exchange yields
an intermediate linked through an a-thioester, which spontaneously rearranges
to a peptide bond. Native chemical ligation can be performed in the
presence of all the functionalities commonly found in proteins, including free
cysteine sulfhydryls. Cysteine residues that are not N-terminal cannot
spontaneously rearrange to give an amide bond, and due to the reversible

nature of the initial trans-thio-esterification step, these side-products are simply
converted back to starting materials in the presence of exogenous thiols.
This advantage has made native chemical ligation the most successful and
commonly used chemical ligation approach.35 Native chemical ligation
(Figure 1.7) is the last step of protein splicing (Figure 1.5 ®) and their
combination allowed the development of the protein semi-synthesis technique
expressed protein ligation (EPL).
EPL permits the ligation of two polypeptides, at least one of which is
recombinant. This methodology is very flexible, allowing ligation of
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Peptide 1 O J . S.

IP*

H-lAl,"

I—

Pepe.de i f f i

__

Pepcide ! " V

Figure 1.7. Mechanism of native chemical ligation. The mechanism is
explained in the text.

polypeptides to take place under a variety of conditions, e.g. in the presence
of denaturants, organic solvents, and detergents.7

In addition, the amino-

terminal OC-thioester fragment can contain essentially any residue next to the
a-thioester.67 EPL has been used for the incorporation of probes into

proteins in vitro (e.g. unnatural amino acids, fluorophores, post-translational
modifications),7 the isotopic segmental labeling of multi-domain proteins,155
and the backbone cyclization of peptides and proteins.20'22
Protein trans-splicing has been used in a similar manner to EPL.

The

process has found a variety of applications in vitro, including protein semisynthesis,87 segmental isotopic labeling,157 control of protein function102 and
cyclization or polymerization of proteins.48
been

used

In addition, split-inteins have

to cyclize proteins in vivo48 126 and

to study protein-protein

interactions in prokaryotic and eukaryotic cells.111 112
was first described

in 2000 and

T h e latter approach

allows protein-protein interactions to be

identified in a manner reminiscent of the yeast two-hybrid system.
proteins k n o w n

to interact (calmodulin and

Two

its target peptide M l 3 ) were
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expressed with one

half of the See V M A

intein and

one

half of G F P .

Interaction of calmodulin and M13 resulted in the generation of GFP via
protein trans-splicing and hence the interaction could be detected by
fluorescence techniques.111 This technique has been applied to other
systems110 and adds to the growing number of reporter protein
complementation approaches designed to rapidly identify novel protein-ligand
interactions.133 Furthermore, it is attractive because it should be amenable
to any cell type.
Protein splicing has many features that make it amenable for the semisynthesis of proteins inside cells, namely; inteins are promiscuous with
respect to their flanking sequences,72 and have demonstrated activity in
cells.111 In addition, EPL is a powerful technique for in vitro manipulation
of proteins,72 and one could expect an analogous technique in vivo, where a
chemical probe is ligated to a protein inside cells, should also prove useful.

Protein Transduction Domains.

Passive diffusion of chemical probes into the cell is limited by the
physical properties of the compound, such as charge and lipid solubility.
There also exists a molecular weight cut-off that limits the size of the largest
lipid-soluble substances able to cross the membrane to -500 Da.86 Though a
variety of methods exist to overcome this limitation (e.g. electrophoresis,
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microinjection, vesicle delivery), they have been difficult to work with and
can damage cells. It was recently discovered that several small regions of
proteins called protein transduction domains (PTD) possess the ability to
transverse biological membranes efficiently.
Two groups independently reported protein transduction, demonstrating
that the Tat protein from the HIV-1 virus was able to enter cells when
added to the surrounding media.56 64 Subsequently, several other proteins
with transducing capabilities were identified, including the Drosophila
homeotic transcription factor ANTP (encoded by the antennapedia gene)75and
the herpes simplex virus type 1 (HSV-1) VP22 transcription factor.44 These
are currently are the most popular.

Table 1.1. Amino acid sequence of the first three characterized PTDs.
PTD Amino acid sequence
HIV-1 Tat "YGRKKRRQRRR"
ANTP «RQIKIWFQNRRMKWKK58
HSV VP22 »'DAATATRGRSAASRPTERPRAPARSASRPRRPE»

The domains responsible for transduction in Tat, VP22 and ANTP
have been identified. The minimal Tat transduction domain consists of
residues 47-57,5052141 whereas in VP22 and ANTP, residues 267-30044 and
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residues

43-58,39

respectively, are required

for transduction (Table 1.1).

Interestingly, all three of these proteins are involved in transcriptional
regulation and it is the PTDs that make contact with nucleic acids. The
commonality between each PTD is the presence of basic amino acids
(arginine and lysine), which might be important for lipid interactions,
penetration of the membrane, or both. Protein-structure-predicting algorithms
strongly suggest that the Tat PTD can adopt an alpha helix conformation,91
and the ANTP PTD is known to be helical when present in the core
homeodomain. However, circular dichroism and NMR spectroscopy have
indicated that the Tat basic domain is unstructured,1992 and the insertion of
prolines into ANTP does not appear to inhibit transduction,37 suggesting that
the helical conformation is not required for the PTDs activity.
Although the mechanism of PTD-mediated transduction is unknown, it
is clear that it does not occur through a classical receptor-, transporter- or
endosome-mediated fashion.95 Indeed, both full-length PTD fusion proteins
and PTD peptides rapidly and efficiently transduce into cells at 4°C,
suggesting that a form of absorptive endocytosis is not responsible.37 141
Additionally, treatment of cells with drugs that impair cellular transport
processes does not inhibit transduction.44 The mechanism of protein
transduction remains a difficult question to address experimentally, but
progress has recently been made. In general, transduction efficiency appears
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to correspond to the number and location of arginine residues in the P T D
sequence. "When a series of arginine-rich peptides (derived from 14 RNAand DNA-binding proteins) were screened, they were all able to trans-locate
through the cell membrane.57 Substitution of basic residues in Tat (49-57)
produces a significant (70-90%) decrease in cellular uptake.148 Furthermore,
the guanidine head-group of the arginine side-chain seems to be a critical
structural feature for transduction. Homo-polymers of citrulline, an arginine
isostere in which the nitrogen of the guanidine group is replaced with
oxygen, show no transduction activity.148 Moreover, increasing the distance
between the guanine group and the peptide backbone had a positive effect
on cellular uptake.100 148 These observations suggest that the guanidine
group is involved in the interaction of the PTD with the cell membrane.
The guanidine group could be forming stable bi-dendate hydrogen bonds
with anions such as phosphate or sulfate100 or the delocalized positive charge
could be making membrane interactions more amicable. Thus, the
internalization of arginine-rich PTDs seems to occur through a specific
interaction between the arginine head-group and charged members of the cell
membrane. These experiments are in accordance with the recent finding
that cell-surface heparin sulfate (HS) proteoglycans are required for protein
translocation (cells genetically impaired in the biosynthesis of fully sulfonated
HS proteoglycans were selectively impaired for transduction).138 The
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ubiquitous presence of H S

could explain w h y Tat peptides and conjugated

proteins are able to enter a wide variety of cells. However, it is still
unknown how PTD-linked macromolecules are internalized following the
interaction with the cell surface, and furthermore the HS PTD interaction
fails to explain the ability of these peptides to shuttle out of cells (no HS
are present in the cytosolic side of the membrane).
A significant barrier to the uptake of hydrophilic proteins is imposed
by the hydrophobic interior of the lipid membrane, and the uptake
mechanism of PTDs must overcome this obstacle. The formation of
membrane channels is unlikely to account for the internalization of large
PTD-conjugated macro-molecules. In addition, Tat-mediated transduction does

Extracellular m e d i u m

y'v', ?•r ^ *

m
Cytoplasm
CSS-SpSt*-.

Figure 1.8.

Inverted micelle formation model for the translocation of

PTD across membranes. The peptides interact with the charged
phospholipids on the outer side of the membrane. Destabilization of
the bilayer results in the formation of an inverted micelle that travels
across the membrane and eventually opens on its cytoplasmic side.
In such a model the peptides never leave an aqueous environment.
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not appear to involve any disruption of the plasma membrane, as uptake of
unrelated non-conjugated peptides present in the incubation media could not
be observed.141 The latter observation demonstrates a key asset of PTDmediated transduction: the ability to deliver a cargo, avoiding the movement
of non-linked molecules into or out of the cell. NMR data has also
demonstrated that the backbones of PTD peptides are flexible, presumably
allowing them to adapt to the concave surfaces of micelles.16. Though a few
models for translocation have been suggested, one of the most commonly
cited is the inverted micelles translocation model38 (Figure 1.8).
PTDs that are chemically cross-linked to heterologous proteins, such as
antibodies and enzymes, have been shown to transduce into cells.3 53 In
addition, the molecules that PTDs can deliver are not limited to proteins2
(Figure 1.9). In 1991 Frankel stated:
"Beyond the possible relevance for HIV infection, the efficiency of uptake
suggests that Tat might prove a useful vehicle for delivering proteins or
peptides into cells" Frankel.95

In the P T D

based delivery system, intracellular concentrations of the

transduced protein are almost identical between cells and can be readily
controlled simply by changing the amount of protein added to the culture
media. Also, PTD fusion proteins are rapidly internalized allowing for
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temporal control.143

For example, the fusion protein can be added to cells

in a manner that is synchronized with a particular phase of the cell cycle
with activity occurring within minutes of protein addition. The same
experiment performed with plasmid DNA transfections would be impossible
because of the large delay between DNA uptake and protein expression. To
date, a large number of proteins have been successfully transduced (Table
1.2).

Smalt/
Fullintermediate
length
molecules PeplKites Antisense proteins

40 nm
Fe beads

200 nun
Liposomes

Cargo

PTD
+ *+

ExItacelUar

^
Intracellular

Figure 1.9.

Utility of protein transduction technology.

A wide variety

of cargo has been covalently linked to arginine-dependent protein
transduction domains (PTDs).
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Table 1.2. Examples of proteins transduced with PTDs.
Protein

Reference

pl6

52

p27

104

E2F

88

P-galactos idase

125

Cdk2

51

C u / Z n superoxide dismutase

84

enhanced G F P

23

Cre recombinase

74

p53

150

caspase-3

142

PEA-15

46

Protein transduction has also been shown to be advantageous over
viral transgene delivery in vivo (e.g. whole
conjugated

protein

results in transduction

animals).
of

100%

Injection of a Tatof the

cells in a

concentration-dependent manner, whereas viral delivery achieves only 3 0 - 5 0 %
efficiency.13 14.
silver bullets.
and

Although

PTDs

have been used extensively, they are not

For example, proteins transduced with T A T

the translocation activity of A N T P

cargo size.119

are denatured,23

is greatly reduced with increased

These latter characteristic may not be ideal for all applications,

but P T D s are well suited to deliver small, un-structured synthetic molecules
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into cells.

In conjunction with protein splicing, P T D s presented a viable

route to investigate semi-synthetic protein synthesis in vivo.
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Thesis Objectives

The objective of this thesis was to explore the union of PTD and
protein splicing in order to achieve protein semi-synthesis in living cells.
First, PTD peptides were evaluated as a means to introduce in vitro
manipulated peptides and proteins into cultured eukaryotic cells. Then,
protein trans-splicing was explored to address the possibility of in vivo protein
semi-synthesis in cells. Lastly, there was a slight divergence from the main
focus of the thesis for the exploration of the utility of semi-synthetic proteins
as a tool to answer biological questions in the context of whole animals.
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C h a p t e r 2 : Results a n d Discussion.

Incorporation of chemically m a n i p u l a t e d peptides a n d proteins into

cultured mammalian cells using PTDs.

A

key feature for the development of protein semi-synthesis inside cells

is the need to shuttle the synthetic component into the cytosol. PTD
peptides have the ability to translocate through cellular membranes and
transport cargo molecules into the cytosol of cells (see chapter l).143 ANTP
was selected for this thesis because its small size, 16 amino acids, makes it
amenable for SPPS.
Three methods are typically used for coupling the cargo molecule to
the PTD. The cargo may be attached via a disulfide bond136, chemically
synthesized in tandem68 or a fusion protein comprising the PTD and cargo
can be expressed in bacteria and purified15 (Figure 2.1).
To explore the translocation activity of ANTP in preliminary
experiments, the PTD was synthesized in tandem within a 70 amino acids
model polypeptide, derived from DnaE, by Boc SPPS. The fluorophore
tetramethylrhodamine (Rh) was attached to the £-NH2 group of Lys6' using an
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A

IpTdI-S-S-I

Cargo

B

IPTDJ

Cargo

C

iPTDl

Cargo"""
Affinity tag

Figure 2.1.

Methods for coupling P T D peptides to a cargo.

(A) The

cargo and P T D can be synthesized separately and attached through a
disulfide bond.

(B) The

synthesized in tandem.

cargo

(C) A

and

PTD

can

be

chemically

fusion protein comprising the P T D

and cargo can be expressed in bacteria and purified.

orthogonal (Fmoc/Boc) protection strategy. (Peptide 1, ANTP is highlighted
in blue and R h in red).
Peptide 1:
H-MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAANCFGCGRQIKI
WFQNRRMKWKKGGDYKDDDDKGK(Rh)G-NH2

The purified peptide was added into the media of HeLa cells growing
in a microscopy chamber

to a final concentration of 1 n M .

After

30

minutes incubation, the cells were washed with Hanks' balanced salt solution
(HBSS) and imaged live with a fluorescence microscope.

A N T P was able to

translocate the 70mer (Peptide 1) into cells (Figure 2.2 A ) and over a period
of an hour it accumulated in the nucleus (Figure 2.2 B ) .

This nuclear
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Figure 2.2.
HeLa

Localization of peptide 1.

cells after 30 minutes

confirmed translocation.

(A) Microscopy imaging of

incubation with

1 nM

peptide 1

(B) A n hour after removing peptide 1 from

the media, the internalized peptide accumulates in the nucleus.

accumulation is well documented for PTDs, including ANTP,119 most of
which have nuclear localization sequences (NLS).
The nuclear localization of peptide 1, due to the tandem inclusion of
A T N P , would ultimately lead to the separate compartmentalization of the
components
process.

of semi-synthesis (nucleus vs. cytosol) and

could

prevent the

Previous studies have shown that P T D s can internalize disulfide

bound cargo and, once inside the reductive environment of the cytoplasm,
the cargo is released from the PTD.134 135

T o verify this, a protocol was

developed that allowed a cargo peptide, derived from D n a E (Peptide 2), to
be coupled to A N T P through a disulfide bond (Figure 2.3 A ) .
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Peptide 2 (later referred to as I^FLAG):

H-MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAANCFN

DYKDDDDKG-NFL

A N T P and peptide 2 were separately synthesized by Boc SPPS and purified.
As shown in figure 2.3 A, a protected cysteine residue was added at the N-

B

A2M nn/mAu
iAu ^
800-

>•• i i
CRQIKIWFQNRRMKWKK

H§v
"1
Dl
MVKVIORRSI.GVQRiroiOU'QDHNPLIANGAIAANCFNDYKDDDDKG

Product

600Reactants
400-

— (7=0
—1=5'

--- fc.

JpH 7.5
2000-,

.

A \ j \r-~_
fi^0

18

22

" t/min

ic-P»

Figure 2.3.

Coupling of peptide 2 to C y s ( N P y S ) A N T P .

(A) General

scheme for the synthesis of ANTP-S-S-Peptide 2 via a nucleophilic
disulfide exchange. The amino acid sequence of peptide 2 and
ANTP are depicted in purple and blue respectively. Highlighted in
orange or in bold are he NPyS group on ANTP and the single Cys
in peptide 2, respectively. (B) RP-HPLC analysis of the conjugation
reaction between Cys(NPyS)ANTP and peptide 2. Linear gradient: 073% B (90% acetonitrile and 0.1% TFA in water) over 30 minutes.
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terminus

of A N T P .

The

sulfhydryl group was

protected with a 3-nitro-2-

pyridinesulfenyl group (NPyS, highlighted in orange in Figure 2.3 A), which acts as
a leaving group upon nucleophilic disulfide exchange with the unique cysteine
within peptide 2 (highlighted in bold). After purification, the peptides were
dissolved together in degassed 50 mM Tris/HCl buffer pH 7.5 to a concentration
of 1 mM in each. The nucleophilic disulfide exchange reaction was allowed to
proceed for 5 minutes at room temperature (becoming visibly yellow as the NPyS
group was being displaced), and then quenched with acid. This reaction allowed
highly efficient (>95%) conjugation of the cargo to ANTP (Figure 2.3 B), and unreacted starting material could be recovered for re-use.
Two disulfide conjugates were used to study if the disulfide conjugation
system allowed delivery of the cargo into the cytoplasm; one bearing Rh tethered to
the ANTP component (Rh-ANTP), and the other with Rh linked to peptide 2
(Peptide 2-Rh). These peptides were independently added onto HeLa cells (to a
final concentration of 2 nM), which were then incubated for 30 minutes before
being washed twice with PBS and fixed with 3.7% formaldehyde, followed by BSA
blocking and nucleic acid staining with Hoechst. The fixed cells were then
analyzed by fluorescent microscopy. As shown in Figure 2.4 A, the Rh-ANTP

peptide was localized throughout the cells, including the nucleus, whereas peptide 2
Rh was predominantly localized in the cytoplasm (Figure 2.4 C). This result

confirmed that the disulfide reduction was taking place inside the cells, dissociati
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the cargo from the P T D and leaving it behind in the cytosol, where it can later
react with other molecules.

COOH
ANTP-S-S-IC-FLAG

Figure 2.4.

COOH
ANTP-S-S-Ie-FLAG

Cellular distribution of ANTP-S-S-Peptide 2 Rh-labeled

peptides. HeLa cells were incubated with either Rh-ANTP-S-S-Peptide
2 (A & B) or ANTP-S-S-Peptide 2-Rh (C & D) at 2 nM for 30
minutes before being washed and fixed. Cells were then analyzed by
fluorescence microscopy: Rh (A & C) and Hoechst (B & D) signals
are shown.

Translocation and delivery of short synthetic peptides into cells was achieved
using ANTP as the PTD. ANTP was able to transverse the membrane of
mammalian cells imbedded in a 70mer. Furthermore, ANTP could translocate a
disulfide linked 48mer, and dissociate from it inside the reductive environment of
the cytosol. The cargo peptide was left in the cytoplasm of living cells to undergo
further reaction (e.g. protein semi-synthesis).
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Protein semi-synthesis in vivo using protein trans-splicing.

Protein trans-splicing has m a n y of the attributes necessary for the semisynthesis of proteins inside cells: inteins are promiscuous with respect to
their flanking sequences,72 split inteins are inactive when expressed
individually,87 " 128 152 they associate exclusively with their corresponding
partner,109 and, specifically for the Ssp DnaE system, the components have
high affinity for each other.96
The methodology summarized in Figure 2.5 was envisioned to produce
semi-synthetic proteins in living cells using protein trans-splicing.
The protein of interest is expressed in cultured cells with the first half
of the naturally occurring Ssp DnaE split intein (L) fused to its C-terminus
(Figure 2.5 (D). Then, a semi-synthetic polypeptide comprised of the second
half of the intein (L) covalently linked to a synthetic probe and a PTD
peptide, is added to the cell media (Figure 2.5 ®). The PTD peptide
would deliver the Ic-probe into the cells, whereupon it can associate with its
complementary half, L, to trigger protein splicing (Figure 2.5 (D). This
would result in the removal of the intein and ligation of the probe to the
selected protein through a normal peptide bond (Figure 2.5 ®). To explore
this methodology, a model system was designed in which the protein of
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Synthetic
Probe

Figure 2.5.
cells.

Principle of semi-synthetic protein trans-splicing in living

L is the first half of the naturally occurring Ssp D n a E intein,

L is its second half and P T D

interest was G F P

FLAG

is protein transduction domain.

and the probe was a short synthetic peptide, based o n the

epitope.

Initially, a bacterial expression plasmid w a s constructed encoding 6xHis-

G F P - L , in order to produce

in vitro

trans-splicing studies.

large e n o u g h

A

standard

quantities to perform

preliminary

His-tag purification protocol

was

used to obtain the protein in relatively pure form (Figure 2.6).
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To

confirm that protein trans-splicing could take place between the

components of the chosen model system, the bacterially expressed 6xHisGFPL was reacted with Ic-FLAG at a final concentration of 100 |lM. (Ic-FLAG =
peptide 2. L and FLAG are highlighted in purple and red, respectively)

Ic-FLAG: (previously referred to as peptide 2)
H-MVKV1GRRSLGVQRIFDIGLPQDHNFLLANGAIAANCFN
DYKDDDDKG-NH,

V
u
OJ
o
M
$

jgtimVuXf

PD

o.
3 \—, <L>
0
Ul tt. C Q
"•'-••hih. -.hp. .'--

50kDafc.
37kDa>

ltr
Commassie stained PAGE-SDS gel
Figure 2.6. Expression and purification of 6xHis-GFP-L from E.
coli. The level of expression induced in bacteria was very high.
The bacterial pellet (A) was bright green when illuminated with
UV light (B). (C) Analysis of the purification procedure by
SDS-PAGE gel showed that most (>90%) of the protein was
insoluble (6xHis-GFP-L is denoted by *), but enough was
recovered to perform in vitro experiments.
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The reaction mixture was incubated at room temperature for 5 hours
and was then analyzed by SDS-PAGE (12%) followed by an anti-FLAG
western blot (Figure 2.7). As shown in the figure, trans-splicing takes place
between 6xHis-GFP-L and L-FLAG, yielding 6xHisGFP-FLAG as the only
splice product (Figure 2.7 lane 2).
Having thus confirmed that semi-synthetic protein trans-splicing was
taking place in vitro, and that Ic-FLAG could enter cells (see previous section),
experiments to address semi-synthetic protein trans-splicing in vivo were
undertaken. A mammalian expression plasmid was constructed encoding
GFP-L driven by the human cytomegalovirus (CMV) constitutively active
promoter (pGFP-L). To confirm expression in mammalian cells, CHO cells
were transiently transfected with pGFP-L using Fugene. After 24 hours of

1 2
il
P IifKiS
P
50kDa»37kDa».
*
25kDa»p
Anti-FLAG blot
Figure 2.7. Anti-FLAG western of in vitro semi-synthetic protein transsplicing. 6xHisGFP-L with no peptide added (lane 1) and 6xHisGFPL with 100 (iM of L-FLAG present (lane 2). The product,
6xHisGFP-FLAG, is denoted by *, and its expected mass is 29 kDa.

39

expression the cells were washed twice with P B S and harvested.

The cell

pellet was resuspended in SDS sample buffer and loaded onto an SDS-PAGE
gel (12%) for blotting against GFP (Figure 2.8), which verified the expression
of GFP-L.
HeLa cells were also transiently ttansfected with pGFP-L to visualize the
localization of the fusion protein. After 24 hours of expression the cells were
washed twice with PBS and fixed with 3.7% formaldehyde, followed by BSA
blocking and nucleic acid staining with Hoechst. As seen in figure 2.9 GFP-L was
distributed throughout the cell.
With the individual pieces in place, semi-synthetic trans-splicing inside cells
was investigated. 10 cm plates of CHO cells were transfected with pGFP-L. After

50kDa».

<

37kD

25kDa^

Anti-GFP blot

Figure 2.8. Mammalian expression of GFP-L. Anti-GFP western blot
of un-transfected CHO cells (lane 1) and CHO cells transfected with
pGFP-L (lane 2). GFP-L is denoted by •, and its expected mass is
42 kDa. Background bands are denoted by < and proteolysis
products by ©.
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24 hours of transient expression, the cells were washed twice with 10 m L of PBS
and fresh media (2.5 mL) containing 0.5% DMSO or 0.5% DMSO with the
ANTP-S-S-Ic-FLAG peptide added to a final concentration of 100 |iM. The cells
were then incubated for three hours before being harvested. The cell pellet was
resuspended in 1 mL of lysis buffer: PBS containing 1% (w/v) docecylmaltoside
(DM), 10 mM iodoacetamide, 2 mM N-ethyl-maleamide and protease inhibitors.
Lysis under alkylating conditions blocks all cysteine sulfhydryl groups, therefore

preventing splicing in vitro. The soluble fraction was immuno-precipitated with anti
GFP or anti-FLAG beads and the captured proteins were loaded onto an SDSPAGE gel and blotted against GFP or FLAG. This procedure allowed us to detect
the presence of proteins containing either GFP or FLAG alone (i.e. the reactants
or potential side-products) or both GFP and FLAG (i.e. the desired product). The
results of this experiment are shown in Figure 2.10.

Figure 2.9.

Cellular localization of GFP-L in HeLa cells. The image

shows that GFP-L is distributed throughout the cell.
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A

band

with

the

expected

molecular weight

for the

semi-synthetic

product (-29 kDa) appeared when transfected cells were treated with the

ANTP-S-S-L-FLAG peptide (lanes 4, 8, 12 and 16). Importantly, this new

band cross-reacted with both the anti-GFP and anti-FLAG antibodies

confirming it was the desired product, GFP-FLAG. In contrast, this new

band was not present in non-transfected and untreated cells (lanes 1, 5, 9

and 13), non-transfected cells treated with the ANTP-S-S-L-FLAG peptide

&
FLAG

GFP
Anti-GFP IP

T"5
T T6 T7 *8'
50kDai
37kDa«

m m
--:•••'

25kDa.

w

Anti-GFP IP

Anti-FLAG IP

Anti-GFP blot

9 10 11 12
50kDafc. i ^ i ^ . & «i:

Anti-FLAG IP
13 14 15 16
..jJt m . •*-*.**% <

37kDafc.
'JL&. *
25 kDa.
Anti-FLAG blot

Figure 2.10. Semi-synthetic trans-splicing b e t w e e n G F P - L a n d L - F L A G
in CHO cells [schematically shown in top panel]. Cells treated as
indicated below were lysed and the soluble fraction immunoprecipitated and blotted as indicated in the panels. Non-transfected
and untreated cells (lanes 1, 5, 9 and 13), non-transfected cells
treated with 100 [iU ANTP-S-S-L-FLAG (lanes 2, 6, 10 and 14),
transfected cells expressing GFP-L with no peptide added (lanes 3, 7,
11 and 15) and transfected cells expressing GFP-L treated with 100
UM ANTP-S-S-Ic-FLAG (lanes 4, 8, 12 and 16). The ligation product
GFP-FLAG is denoted by *, GFP-L is denoted by •, background
bands are denoted bv < and proteolysis products are denoted bv ©.
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(lanes 2, 6, 10 and 14) and transfected cells with no peptide added (lanes 3,
7, 11 and 15).
Interestingly, GFP-L co-immuno-precipitated with L-FLAG (lane 8)
indicating a non-covalent complex between the two components. This
suggests that protein splicing, and not split-intein association, is the ratedetermining step in the process, which is in accordance with previous studies
on Ssp DnaE-mediated protein trans-splicing.96 Furthermore, co-immunoprecipitation of GFP-L but not of the proteolysis products, suggested that the

3

37kDai*lP!SP^^

4

37kDa*-

5

6

37kDa^|

j©
! ©
25kOafc. 25kDafc-8 25kDafc-|.'.
A

Figure 2.11.

Anti-GFP IP
Anti-GFP blot

g

Anti-FLAG IP
Anti-GFP blot

q

Anti-FLAG IP
Anti-GFP blot

Semi-synthetic protein trans-splicing takes place in cells.

(A 6k B) Transfected cells expressing GFP-L with no peptide added
at the time of lysis (lane 1 & 3) and transfected cells expressing
GFP-L treated with 50 uL of 100 JIM Ic-FLAG at the time of lysis
(lane 2 & 4). (C) Transfected cells expressing GFP-L treated with
100 fxM ANTP-S-S-L-FLAG (lane 5) and transfected cells expressing
GFP-L mixed at the time of lysis with non-transfected cells treated
with 100 mM ANTP-S-S-Ic-FLAG (lane 6). The ligation product GFPFLAG is denoted by *, GFP-L is denoted by •, proteolysis products
are denoted by © and background bands are denoted by <.
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degradation of the over-expressed protein was taking place C-terminally (at L)
(lane 3 (St 4, indicated by 0); proteolytic fragments were not associating or
reacting with Ic-FLAG.
The anti-FLAG IP analysis also demonstrated that the trans-splicing
reaction is specific as only one protein was tagged with FLAG (lane 16).
The efficiency of the semi-synthetic protein trans-splicing reaction could not
be easily determined, because GFP-L was being continually expressed (and so
therefore not depleted) and because the ANTP-S-S-Ic-FLAG peptide was added
in large excess. Finally, the generation of the semi-synthetic product provides

37kDa m.

*
25kDa m.

Anti-FLAG IP.
Anti-GFP blot
Figure 2.12. FLAG labeling of GFP is due to protein splicing.
Transfected cells expressing GFP-L treated with 100 uM ANTP-S-S-LFLAG (lane 1), transfected cells expressing GFP-L treated with 100
UM ANTP-S-S-L(S-R)-FLAG (lane 2) and transfected cells expressing
GFP-L(Ala-) treated with 100 uM ANTP-S-S-Ic-FLAG (lane 3). The
ligation product GFP-FLAG is denoted by *, GFP-L is denoted by •
and background bands are denoted by <.
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unequivocal proof that Ic-FLAG was released from A N T P

since this process

(i.e. disulfide reduction) unmasks the reactive cysteine within L required for
splicing.

Further control experiments were performed to completely rule out the
possibility that splicing was taking place in vitro (i.e. after lysis). The issue
was addressed in two ways. The first experiment consistent in adding 50 flL
of 100 |LtM of Ic-FLAG onto the cells at the time of lysis (Figure 2.11 A &
B) .The second experiment consistent in mixing transfected cells expressing
GFP-L, but not treated with the peptide, with non-transfected cells treated
with the peptide at the time of lysis (Figure 2.11 C). The two components
of the trans-splicing system were present throughout the in vitro manipulations
in both cases, such that, if trans-splicing was taking place after lysis, the
activity should be detected. As shown in Figure 2.11, no splicing or splitintein association was detected (compare lanes 1 & 2, 3 <Sc 4 and 5 <St 6).
To confirm that product formation was due to protein splicing, an
experiment was performed using inactive forms of L or L. The reactive
cysteine in L was mutated to an alanine (GFP-L(Ala250) and reactive cysteine
in L was alkylated and an extra cysteine added onto the N-terminus of the
peptide for disulfide linkage to ANTP (L(S-R)-FLAG). Although the inactive
L and L analogs were able to associate with their complementary
component, in neither case was trans-splicing observed (Figure 2.12, lanes 2
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Figure 2.13. Generality of protein semi-synthesis in vivo. (A) Anti-GST
western blot of 12% SDS-PAGE gel of un-transfected and untreated
cells (lane 1), cells transfected with pGST-L left untreated (lane 2)
and cells transfected with pGST-L treated with peptide (lane 3). The
product GST-FLAG is denoted by *, and its expected mass is -28
kDa. The precursor GST-L is denoted by •. (B) Anti-FLAG western
blot of a 15% SDS-PAGE gel of un-transfected and untreated cells
(lane 4), cells transfected with pDHFR-L left untreated (lane 5) and
cells transfected with pDHFR-L treated with peptide (lane 6). The
product DHFR-FLAG is denoted by *, and its expected mass is
-24.5 kDa. (C) Anti-GFP western blot of a 15% SDS-PAGE gel of
un-transfected and untreated cells (lane 7), cells transfected with
pYFP-In-CFP left untreated (lane 8) and cells transfected with pYFP-LCFP treated with peptide (lane 9). The product YFP-FLAG is
denoted by ~k and its expected mass is -29 kDa. Background bands
are denoted by <.

&. 3). Thus product formation occurs via protein trans-splicing in the living

cells.

To explore the generality of protein semi-synthesis in vivo, Ic-FLAG was

reacted with three other model cytosolic proteins: GST-L, DHFR-L and YFP-

In-CFP and in each case the desired semi-synthetic product was obtained
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(Figure 2.13).

Interestingly, the later construct ( Y F P - L - C F P ) s h o w e d

improved

cytosolic expression as compared to GFP-L (Figure 2.14), suggesting that

inserting L between two domains may help soluble expression of the fusion

protein. In addition, trans-splicing resulted in cleavage of YFP from L-CFP,

indicating that the methodology may also serve as a tool to trigger the un-

coupling of fusion proteins in vivo.

In principle, the protein semi-synthesis approach based on protein

trans-splicing should also be applicable to integral membrane proteins. This

possibility was investigated by preparing a semi-synthetic version of the G-

1 2

3

4 5

lOOkDai
50kDal
37kDal

•mm

25kDafc ;'.••:.,,.•.

75kDa»

mm*****
50kDa» ;'Z-

A Anti-GFP blot B Anti-GFP blot

Figure 2.14. Comparison of whole cell vs. detergent soluble or insoluble
expression of GFP-L and YFP-L-CFP. CHO cells were transiently
transfected with either pGFP-L (A) or pYFP-L-CFP (B) and after 24
hours of expression the cells were lysed in PBS + 1% DM. Whole
cell (lanes 1 & 4), soluble (lanes 2 &. 5) or detergent insoluble
fraction (lanes 3 & 6) samples were loaded for analysis onto a 12%
PAGE-SDS gel and blotted against GFP. In the case of GFP-L
>90% of the protein is insoluble (compare lanes 2 & 3) vs. -50% in
the case of YFP-L-CFP (compare lanes 4 & 5). GFP-L is denoted by
•, and its expected mass is -42 kDa. YFP-In-CFP is denoted by A,
and its expected mass is -74 kDa.
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protein-coupled receptor ( G P C R ) , Opsin.

As shown in Figure 2.15, Opsin-

GFP-FLAG was generated by treating transfected cells expressing Opsin-GFP-L
with ANTP-S-S-L-FLAG (compare lane 3 with control lanes 1 ek 2).
Importantly, the smearing of the band corresponding to the ligation product,
Opsin-GFP-FLAG, is consistent with glycosylation of this protein, known to

75kDa

m*«.Am <
50kDa
Anti-FLAG IP.
Anti-GFP blot
Figure 2.15. Semi-synthetic trans-splicing between Opsin-GFP-L and LFLAG in CHO cells [schematically shown in top panel]. Cells treated
as indicated below were lysed and the soluble fraction immunoprecipitated and blotted as indicated in the panel. Non-transfected
and untreated cells (lane 1), transfected cells expressing Opsin-GFP-L
with no peptide added (lane 2) and transfected cells expressing
Opsin-GFP-L treated with 100 uM ANTP-S-S-Ic-FLAG (lane 3). The
ligation product (Opsin-GFP-FLAG) is denoted by *, background
bands are denoted by <, and the smearing in the band is due to the
glycosylation of Opsin. The expected molecular weight of Opsin-GFPFLAG is -70 kDa.

48

occur during membrane integration.77
Preliminary experiments were performed to determine the minimum
concentration of ANTP-S-S-L-FLAG needed to observe semi-synthetic transsplicing within 3 hours of incubation (Figure 2.16). CHO cells expressing
GFP-L for 24 hours were treated for 3 hours with varying concentrations of
ANTP-S-S-L-FLAG. Following harvest and immuno-precipitation against
FLAG, samples were analyzed by western blotting against GFP. As seen in
figure 2.16, a minimum of 50 LiM was required to observe activity or
association of the fragments at this time point. This observation is rather

12 3 4 5 6 7
50kDa

,VV ••',. . • '•••' • .•'/• • "•' r, .

37kDa

25kDal
Anti-FLAG IP.
Anti-GFP blot
Figure 2.16. Minimum concentration of L-FLAG necessary to observe
semi-synthetic protein trans-splicing in cells. Un-transfected and nontreated cells (lane 1), transfected cells expressing GFP-L with no
peptide added (lane 2) and transfected cells expressing GFP-L treated
with 100 uM (lane 3), 50 oM (lane 4), 10 JlM (lane 5), 5 |lM (lane
6) or 1 (iM (lane 7). Product formation or intein association is only
seen at 100 or 50 [iM (lanes 3 6k 4). The ligation product GFPFLAG is denoted by *, GFP-L is denoted by • and background
bands are denoted by <.
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surprising, as literature reports have suggested that the dissociation constant
(Kd) between L and L is in the nano-molar range.96 The possibility that
only a small percentage of the L-FLAG is being translocated is unlikely,
because transduction of both ANTP and Ic-FLAG was observed at 2 nM (see
previous sub-section). Future experiments will be required before the origins
of this observation are known.
Although protein semi-synthesis based on trans-splicing allows
ligation to both cytosolic and membrane bound proteins in vivo, the
technique is not without drawbacks. Addition of L to the C-terminus of
proteins affects their solubility, and in the case of membrane bound proteins,
their localization. Solubility problems with split inteins have been previously
reported and can possibly be due to improper folding or exposed
hydrophobic regions.99128 As seen in figure 2.14 (compare lanes 2 <Sc 3)
most of the GFP-L is expressed in an insoluble form. To partially overcome
this issue, L was inserted between two GFP proteins to stabilize it and
increase its solubility (Figure 2.14, compare lanes 2 <Sc 3 with 5 <Sc 6). This
protocol also increased expression of the membrane bound transferrin
receptor (TnfR) tagged with GFP-L (Figure 2.17, compare B & C), but did
not overcome the undesired (e.g. endoplasmic reticulum (ER)) localization
observed with the tandem expression of TnfR and L. As seen in figure
2.17, TnfR-GFP localizes to the cell surface of mammalian cells as desired
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Figure 2.17. Localization of TnfR-GFP, TnfR-GFP-L and TnfR-YFP-L-CFP
in MCF-7 cells. Cells were transiently transfected and allowed to express
the proteins for 24 hours, before being fixed.
localized to the plasma membrane.

(A) TnfR-GFP is

(B) TnfR-GFP-L does not localize to

the plasma membrane, and is scarcely visible. (C) TnfR-YFP-L-CFP does
not localize to the plasma membrane, but it expresses better then TnfRGFP-L.

G F P (A &

B) or YFP (C) fluorescence signal is shown.

(Figure 2.17 A ) , contrary to both TnfR-GFP-L and TnfR-YFP-lN-CFP, which
appeared to be largely retained in the E R (Figure 2.17 B

&. C ) . This type

of undesired localization was also observed with Opsin-GFP-L (Figure 2.18
compare A

&. B ) .

In a previous study, Ozawa et. al. attached L
proteins, but did not visualize their localization.110
exposure of hydrophobic residues of L
inadequate delivery of membrane proteins.

may

to m e m b r a n e

bound

Improper folding or

also be responsible for the

Additionally, the size of L (123

amino acids) could have an effect, analogous to that observed in some cases
w ith G F P

tagging.

Further studies on L

intein fragment behave better.
improve its characteristics.

may reveal a way to make this

Mutagenesis, or minimization of L

could

Alternatively, inverting the system (e.g. L tagged
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Figure 2.18. Localization of Opsin-GFP and Opsin-GFP-L in H e L a cells.
Cells were transiently transfected and allowed to express the proteins for
24 hours, before being fixed.
membrane.

(A) Opsin-GFP is localized to the plasma

(B) Opsin-GFP-L does not localize to the plasma membrane.

G F P fluorescence signal is shown.

to

the

protein

of

interest

and

L

used

to

deliver

the

probe) could

together by-pass these solubility a n d localization problems as L

all

is small and

seemingly well behaved (see below).

W h i l e Ic-FLAG was synthesized by S P P S for this study, a semi-synthetic

protocol for the addition of probes onto L

flexibility.

was also developed for ease a n d

T h e approach, based o n E P L , is summarized in Figure 2.19.

Cys-

GyrA-CBD

^
Thiols

Figure 2.19. General scheme for the addition of a probe onto L.
CBD

is expressed

in bacteria and

domain ( C B D ) or other affinity tag.

Ic-GyrA-

purified using the chitin binding
O n c e purified it can react with a

N-terminal cysteine containing probe to give the desired product: Lprobe.
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Figure 2.20. Bacterial expression and purification of Ic-GyrA-CBD. The
fusion protein was soluble, and was induced to very high levels (-50%
of the total bacterial proteins).
expected mass is
A

Ic-GyrA-CBD is denoted by •, and its

32 kDa.

bacterial expression plasmid was constructed with L

N-terminally

fused to the mutated Gyrase A

(GyrA) intein followed by a chitin binding

domain ( C B D ) (pIc-GyrA-CBD).

Expression was induced to high levels in E.

coli, and the soluble fusion protein was purified over chitin beads (Figure
2.20).
The G y r A intein within the purified fusion protein was functional and
permitted E P L between L
(Figure 2.21).

and peptide 3 to take place in yields of > 9 0 %

T h e product (L-Peptide 3) bound

non-specifically to chitin

beads, but was effectively eluded with a solution containing 8 M

urea.
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1

2

3

4

37kDafc-©

25kDa I

Iftttjil "k

Figure 2.21. L-GyrA-CBD is functional and undergoes EPL. Untreated
protein (lane 1), protein cleaved with 100 m M
protein treated with 1 m M

MESNA

(lane 2),

of peptide 3 is unmodified (lane 3) and

protein treated with 100 m M

MESNA

and

produces the expected product Ic-Peptide 3.

1 mM

of peptide 3

Full length Ic-GyrA-CBD

is denoted by •, cleave GyrA-CBD is denoted by ® , and the EPL
product Ic-Peptide 3 is denoted bv *.
Peptide 3:
H- C G R G K ( R h ) G - N H ,
Protein semi-synthesis in vivo
successful.

based

on

protein

trans-splicing was

In principle, any synthetic molecule - a polypeptide or, minimally,

a cysteine derivative bearing any chemical moiety - can be
protein of interest inside living cells.

ligated to a

Here, incorporation of the probe took

place at the C-terminus of the protein, however, by interchanging the split
intein components, it should be possible to introduce the probe at the Nterminus of a protein as well.
the approach.

Future experiments will be performed in the laboratory to

explore N-terminal ligations.
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Such a possibility increases the modularity of

Semi-synthetic g r o w t h factor derivatives for w h o l e a n i m a l studies.

TTiis work was done in collaboration with Rob Flavell and Amersham Health.

Growth

factors are extra-cellular polypeptide

signal molecules that

stimulate a cell to grow, proliferate, differentiate or survive.85 They circulate
in the blood stream and have specific receptors on the surface of target
cells. Most animal cells require a precise combination of several growth
factors to multiply, highlighting the combinatorial nature of the associated
signaling pathways, and the need to study these polypeptides imbedded
within their in vivo system. Furthermore, growth factors are tightly associated
with the uncontrolled cell division seen in tumors and cancer.85 These
characteristics make growth factors an interesting and suitable proof-ofprinciple system for the investigation of protein semi-synthesis as a tool for
whole animal studies. Initially, the vascular endothelial growth factor (VEGF)
was chosen as a model protein.
VEGF is a critical regulator of angiogenesis, the formation of new
blood vessels, and plays an important role in vascular development and
wound healing.55 VEGF-mediated angiogenesis is also implicated in a variety
of pathological conditions, most notably the vascularization of solid tumors.
Thus, there is great interest in understanding the role of VEGF in normal
and aberrant vascular development and whether this function can be
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Figure 2.22. Splice variants of h u m a n V E G F .
through alternative splicing produces 5
presence

or

absence

of heparin

respectively.

iso-forms, which

binding

represent the pro-peptide sequence

and

The human

domains.

V E G F gene,
differ in the

Black

the receptor-binding

and

red

domain,

Other colors represent heparan-sulfate proteoglycan ( H S P G )

binding domains encoded by different exons.

V E G F u o is the proteolytic

product of VEGF.65 or VEGFis..
exploited for the development

VEGF

of n e w

therapies for disorders like cancer.54

is a homo-dimeric, disulfide-linked glycoprotein that is secreted

the extra-cellular space.

which

It has multiple splice variants (Figure 2.22), all of

contain a signal peptide sequence

domains.

can be

into

for secretion a n d

heparin

In the case of VEGFies and VEGFi89, the heparin binding

binding

domains

cleaved off by the protease plasmin, producing the freely circulating

VEGFuo.55

VEGF

(Figure

2.23),

predominantly

conditions
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binds to specific receptors, including V E G F R - 1

with

pico-molar

in endothelial

or by

the

increase

affinities.

cells a n d

These

can

in ligand

be

receptors

up-regulated

concentration

that

and

VEGFR-2

are

expressed

under

occurs

hypoxic

during

angiogenesis.

High

concentrations

of V E G F R - 1

and

VEGFR-2

serve as

markers of active angiogenesis.55 For these reasons, VEGF has been used in

several studies to deliver specific cytotoxic proteins to cells expressing VEGF

receptors as a potential cancer therapy.5 8 9

A circulating variant of VEGF, such as VEGFuo, coupled with an

appropriate imaging tag, could be used as a probe to detect angiogenesis in

whole animals. VEGFuo lacks heparin-binding activity, potentially increasing

its bio-availability,80 but maintaining its high affinity for VEGFR-1 and

VEGFR-2. As endothelial cells are among those exhibiting the lowest

replication level in the body, (with only 0.01% cells engaged in cell division

at any time108), site-specific localization of a radio-labeled semi-synthetic VEGF

VEGF
•binding
domain

Dimetization i
domain

M g like domains

Tyrosine
kinase domain

VEGFR-1

VEGFR-2

Figure 2.23. M a i n V E G F receptors.
receptors of the V E G F
shown.

VEGF

VEGFR-3

T h e three signaling tyrosine-kinase

family (VEGFR-1, V E G F R - 2 and V E G F R - 3 ) are

is also k n o w n

to bind

the accessory iso-form specific

receptors neuropilin-1 and neuropilin-2, and heparan-sulfate proteoglycans.
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onto V E G F R - 1

and V E G F R - 2 should concur with sites of angiogenesis (e.g.

tumors).
Synthetic chelators of the radio-isotope ""To have been conjugated to a
variety of peptides, and used to image pathological events such as blood
clotting, inflammation, infection, and cancer.26 122 158 In particular,
epidermal growth factor has been labeled with "mTc and used to image
tumors in mice.121 Antibodies and other proteins have also been labeled
with "°Tc through standard conjugation methods, including alkylation of
reduced cysteines, biotin-avidin interactions, or the addition of specific "°Tc
chelating peptide sequences.58 59 144
"mTc has proven to be a versatile isotope because it is a pure y
emitter with optimal emission energy of 140 keV, ideal for use with y
cameras employed in nuclear medicine.4 Additionally, its half-life of 6 hours
and ease of production using a MMo/""Tc generator make it well suited for

SnCL
NH H > L /
Y
^

^
OH

OH

•
TcO,
PH9.0

I I
>>s\ /
.

.

O-^/0

Figure 2.24. Diamine, dioxime chelates bind "°Tc in a pyramidal
complex. Loading of w™Tc is achieved under reducing conditions at
pH

9.0.

The

covalent interaction is stable under physiological

conditions.
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diagnostic use.

A

variety of high affinity synthetic chelators for "°Tc have

been developed12 (see below) and loading with "-To is a relatively simple
procedure (Figure 2.24).
The methodology summarized in Figure 2.25 was envisioned to
produce semi-synthetic VEGF with a small imaging tag that chelates "°Tc
with high affinity. Following protein semi-synthesis, the ""Tc would be
incorporated into the protein and allow imaging of the proteins' localization
to vascularized tumors.
In this methodology, VEGF is first bacterially expressed fused to the

/

NQH

EPL
Loading with
Technetium 99m

W

Injection into
Mouse with a
human tumor
•

Semi-synthetic V E G F
Derivative labeled
with 99mTc
Figure 2.25. G e n e r a l s c h e m e to investigate the use of semi-synthetic proteins

produced by EPL in whole animal studies. VEGF was chosen as a model
protein to be tagged with a WnTc chelator. The semi-synthetic protein
could allow imaging of tumors in animals.
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modified G y r A

intein.

A

synthetic cysteine derivative containing a high

affinity chelator of 99mTc is then reacted with the purified protein, resulting
in a semi-synthetic form of VEGF tagged with the chelator (Figure 2.25 CD).
In the next step, the semi-synthetic protein is loaded with "°Tc and injected
into mice bearing a human tumor (Figure 2.25 ® &. ©). Imaging of the
mice with a y-camera would allow the localization of VEGF to be visualized
(Figure 2.25 © <Sc ®). This project was conceived in collaboration with
Amersham Health, one of the world's leading biomedical imaging companies.
In addition, VEGF, a disulfide linked dimeric protein, would further test the
scope of the EPL methodology.
The crystal structure of VEGFmo5 in complex with the VEGF binding
domain of VEGFR-1 has been solved.149 Analysis of the structural data
shows that the C-terminus of VEGF8.io9 is not involved in receptor binding.
Moreover, mutagenesis of this region has little effect on VEGFR binding.81
Therefore, to minimize possible disruption of the interaction between VEGFuo
and its receptors due to an unnatural moiety, the ""Tc chelator was ligated
onto the C-terminus of VEGFuo. An affinity handle was later attached to
the chelator because in preliminary studies, hydrolyzed material could not be
resolved from the ligation product (see below) (Figure 2.26).
VEGFuo was expressed in E.coli N-terminally fused to the cleavable
intein GyrA and a CBD. The majority of the fusion protein was expressed

60

in inclusion bodies.

These were washed with a solution containing 2

M

urea to remove loosely associated proteins, before being solubilized with a
solution containing 8 M urea. Previous work in the Muir laboratory has
shown that GyrA can be refolded from inclusion bodies and it regains
protein splicing activity.139 Such a characteristic makes GyrA a suitable intein
for fusion with VEGFuo, a protein known to go into inclusion bodies when
expressed in bacteria.30 The solubilized VEGFno-GyrA-CBD was refolded by

Chelating moiety
' £~, N

Affinity tag

t ' \

N OH

^
+

HS.

H:

NH

HzNHHHHHH. iJN
©T °

OH
O

Peptide 5

N°H
HS. HSN *^
IN HHHHHHy«,,n p--1 "Y^K

NOH
^O^OH

Figure 2.26. Preparation of semi-synthetic VEGFuo by EPL.

CD VEGFno-

GyrA-CBD is reacted with peptide 5 to produce the monomer form of
semi-synthetic VEGFuo-Peptide 5, and is purified away from hydrolyzed
VEGFuo and un-reacted chelator. © The chemically homogenous
VEGFuo-Peptide 5 can then be refolded into the dimeric and biologically
active form according to literature procedures.
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dialysis using the reported

procedure,139

and

affinity purified

over

chitin

beads. An initial concern was the possibility that the eight cysteine residues
in VEGFuo could cleave the protein away from the GyrA-CBD. Previous
experiments had shown that appropriately placed cysteines could induce in
vivo cleavage of the intein domain.20 However, as seen in figure 2.27, no in
vivo cleavage was detected by SDS-PAGE analysis of the crude cell lysate or
the affinity purified protein.
Amersham Health supplied five different 99mTc chelators (Figure 2.28),
each were bi-functional, containing an N-terminal cysteine (necessary for NCL
St EPL) and a C-terminal 99mTc chelating moiety. Scheme 2.1 shows the

rt <S
rt K
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3 S •s 3
s .s •; -s s ^ s g s

75kDa»50kDa^ I
37kDa*- » «•«• ••*•*«- «• «• •
*
«•>
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p
25kDafc> \ . .- |,

Figure 2.27. Expression and purification of VEGF.,o-GyrA-CBD. VEGFnoGyrA-CBD is denoted by •, and its expected mass is 40.5 kDa. ®
denotes where the GyrA-CBD would be if in vivo cleavage were taking
place.
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synthetic

strategy

used

to

prepare

SN1400-01.

All other

chelators

were

synthesized in a similar fashion.

In preliminary experiments it was shown that all of the molecules

were stable to the reaction conditions used in NCL and EPL. In particular,

there was no decomposition of the oxime moieties in the presence of high

concentrations of thiols (Scheme 2.2). Furthermore, all chelators could

,iNkXv

HS

8H

if
SN 1321-01
SN 1400-01

OH
fu
H:
HC
SN 1326-01

NOH
SN132S01

SN132401

Figure 2.28. ""Tc chelators supplied by Amersham Health. Chelators are
labeled with their identifying numbers. All of the molecules were stable
to the reaction conditions used in NCL and EPL conditions.
Furthermore, they could all ligate to a small Oi-thioester peptide and a
protein tagged with an intein.
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All other chelators provided

by Amersham Health were synthesized in a similar fashion.
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N—OH
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Scheme 2.2. Possible decomposition of oxime moieties to a thio-ketal in the
presence of high concentrations of thiols.

This reaction was not observed

with any of the chelators tested.
undergo efficient N C L

with a model a-thioester peptide, and E P L with a

model protein (Crk-SH3) (data not shown).
Initial E P L studies between VEGFno-GyrA-CBD and S N 1400-01 yielded
the desired ligation product and a side product.

D u e to hydrolysis of the

a-thioester during the ligation reaction, the free carboxylic acid of V E G F u o
was

also generated

(Figure

2.29

B).

The

two

products could

not be

separated by chromatographic techniques, such as R P - H P L C , ion exchange
chromatography, and affinity chromatography.

Upon

oxidative refolding,30

three different dimers were produced: the two homo-dimers and the heterodimer (Figure 2.29 C ) . These three compounds were similarly inseparable by
chromatography.

T h e generation of a heterogeneous mixture using a one-step

ligation protocol underlined

the need

for an

alternative tactic for the

preparation of the desired product in a chemically homogenous form.
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In principle, attachment of an affinity handle to the chelator should
provide a strategy for purifying the final ligation product away from starting
material or side-products (e.g. hyrolysis). Therefore a sequential ligation
approach was developed to incorporate the secondary purification tag (Figure
2.30). The devised method permits modularity and bypasses the need to
synthesize the chelators with the affinity handle (possibly a complicated
synthesis).
Key to this strategy is the reversible protection of the N-terminal
cysteine in the affinity tag. In the absence of such protection, cyclization or
polymerization would occur in the first ligation step (Figure 2.30 CD). To
conceal the N-terminal cysteine a thiazolidine masking strategy was chosen.140
The encrypting moiety is removed upon treatment with methoxylamine,
which is mild, easy and efficient (Figure 2.30). Although the thiazolidine
masking methodology was well suited for this study, other strategies for the
concealment of N-terminal cysteines, such as leader sequences that can be
proteolytically removed47 or chemical protecting groups, such as the 2(methylsulfonyl) ethyloxycarbonyl (Msc) group,131 156 are also available, and
may be appropriate in different contexts.
While virtually any affinity tag could be used, a 6xHis tag was chosen
due to its compatibility with denaturants and mildly reducing conditions
necessary to maintain VEGF as an unfolded monomer during purification.
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Figure 2.30. General strategy for tandem ligation of an affinity tag and a
chelator onto VEGFuo.

©

The chelator is ligated to an affinity tag

containing a thiazolidine derivative that serves as a cryptic N-terminal
cysteine. ©

After ligation, the cysteine is unmasked by methoxylamine

treatment, and can then undergo ligation with VEGFno-GyrA-CBD ® .
The 6xHis tag (peptide 4) was synthesized by Boc SPPS on a 3mercaptopropionamide derivatized PEGA resin, as outlined in figure 2.31 CD.
The N-terminal cysteine of the peptide was incorporated as a thiazolidine
derivative (thiaproline). The only protecting groups on the peptide were
dinitrophenyl (DNP) groups on the histidine residues, which allowed for an
easy and efficient de-protection and cleavage from the resin in a single step
(overnight treatment with 10% aqueous ethanethiol). Peptide 4 was then
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Figure 2.31. N C L between peptide 4 and chelator SN1325-01 to produce
peptide 5. CD The 8 amino acid a-thioester peptide 4 was synthesized
by Boc SPPS on a 3-mercaptopropionamide derivatized PEGA resin.
The N-terminal cysteine of the peptide was incorporated as thiaproline.
De-protection and cleavage from the resin in a single step (overnight
treatment with 10% aqueous ethanethiol) resulted in the production of
the OC-thioester Peptide 4. © Peptide 4 was then reacted with SN132501 to produce the protected peptide 5. © After ligation, the cryptic Nterminal cysteine in peptide 5 was unmasked by the addition of
methoxvlamine.
reacted with SN 1325-01 using 100 mM MESNA as the thiol co-factor to

produce the cysteine protected peptide 5. Unmasking of the cryptic N-

terminal cysteine was accomplished by the addition of methoxylamine.140

The latter reaction very clean with no side-products.
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VEGFno-GyrA-CBD was then reacted with purified peptide 5 generating
the desired ligation product (VEGFuo-Peptide 5) and the free carboxylic acid
of VEGFuo previously described (see above). However, unlike initial
experiments, VEGFuo-Peptide 5 could now be purified away from the sideproduct. Gel filtration chromatography, under denaturing and mildly
reducing conditions, first removed un-reacted peptide 5 and thiol cofactors.
The VEGFuo-Peptide 5 was then purified away from hydrolysis product by NiNTA chromatography. The chemically homogenous VEGFuo-Peptide 5 was
refolded according to literature protocols,30 and the dimeric product was
purified by gel filtration chromatography. The final product was analyzed by
non-reducing SDS-PAGE, RP-HPLC and ES-MS, and confirmed to be the
homo-dimer of VEGFuo-Peptide 5 (Figure 2.32). Thus addition of the
secondary affinity tag allowed recovery of the desired ligation product, which
upon formation of the homo-dimer can be applied to studies in whole
animals.
The purified semi-synthetic VEGFuo-Peptide 5 dimer was tested for
biological activity using an endothelial cell proliferation assay.31 Human
umbilical vein endothelial cells (HUVEC) were stimulated with either the
semi-synthetic protein or commercially available VEGFm (R&D Systems).
Cell proliferation was measured by radiolabeled thymidine, and the EC»s
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were determined to be 591.6 p M

(150.5 - 2325 p M ; 95%CI) and 41.1

pM

(11.9 - 141.7 pM; 95% CI) for VEGF„o-Peptide 5 and VEGFm, respectively
(Figure 2.33). The ten-fold discrepancy in the obtained EC» values could be
due to experimental errors (in particular in the concentrations of the stocks),
or to unforeseen detrimental effects due to the presence of the chelator.
Nonetheless, VEGFuo-Peptide 5 still binds with high affinity and has maximal
potency.
The

dimeric and biologically active semi-synthetic VEGFuo-Peptide 5

A

l 2 3

50kDa»».
37kDa»«
25kDa»- I

27000 m knul

Figure 2.32. Analysis of the VEGF..o-Peptide 5 homo-dimer.
reducing S D S - P A G E analysis.

(A) Non-

Crude refolding mixture (lane 1), gel

filtration purification of dimer (lane 2) and reduction of the dimer with
DTT

(lane 3).

(B) RP-HPLC

(0-73% B) and (C) ES-MS analysis.

VEGFuo-Peptide 5 homo-dimer is denoted by •• ( O M = 27762.9 ± 13.0;
E M = 27755.4).
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sample was sent to A m e r s h a m Health for "-Tc loading and imaging in whole
animals. Male C57BL/6 mice were injected sub-cutaneously in their inner
right thigh with Lewis Lung carcinoma cells. Tumors were allowed to
develop for 15 days, as previous model studies demonstrated that this time
point showed the highest level of tumor angiogenesis. VEGFuo-Peptide 5 was
radiolabeled with "mTc with a low stoichiometry, under a nitrogen
atmosphere, using a standard protocol.93 Radiolabeled VEGFuo-Peptide5 was
the injected into tumor bearing animals via their tail vein. Animals were
killed and dissected at different time points after injection to determine the
bio-distribution of the semi-synthetic protein. J camera imaging revealed that
y-radiation localized to the tumor, the urinary tract, spilt urine, liver, and
kidneys (Figure 2.34). Furthermore, VEGFuo-Peptide 5 was up-taken with
little gastric intestine (GI) excretion, suggesting that it is binuing to its
receptors. Displacement experiments with cold VEGF are in progress to
determine the specificity of VEGFuo-Peptide 5 binding.
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Figure 2.33.

Endothelial cell proliferation assay.

Incorporation of

radiolabeled thymidine by H U V E C in response to VEGFno-Peptide 5 (•)
or VEGF.2. (t). The average count per minute (CPM) of untreated cells
was 550. The experiments were performed in triplicates.
Although

VEGFno-Peptide

5

localized

to the tumor, the negative

control (hVEGFuo without a chelator) had a similar y emmission distribution
in mice, however the level of contrast was inferior to that obtained with
VEGFno-Peptide
intrinsic

5.

affinity

mechanism.

One
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mechanism

sequences present within V E G F .

suggests that V E G F
bind
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99mTc through
involve

the

may

have

an

an

alternative
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GlyGlyCys

These sequences have been reported to

bind 99nTc within a variety of proteins, under the labeling conditions used.17
58 129
labeling

Varying the ""Tc loading procedures or adding free chelators after
may

help

reduce background

99mTc labeling of control VEGFuo.

Additionally, lengthening the time before imaging could allow better images
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to be

obtained.

Such

experiments are currently underway at A m e r s h a m

Health.
It is important to note that in addition to the experiments underway
at Amersham Health, the modular synthetic strategy developed can also be
used to sidestep VEGF "mTc labeling issues. For instance, the imaging tag
can be easily changed to a near-infrared (NIR) fluorophore. NIR
fluorescence imaging, with the advantage of minimal light absorption by
hemoglobin and water,147 could by-pass the problems observed, while still
permitting imaging of angiogenesis. Alternatively, the protein may be
exchanged to a tumor specific single chain antibodies. The modularity of
protein, imaging tag, and affinity handle allows for the exploration of a
number of proteins within a whole animal setting. Future experiments in
the Muir laboratory, in collaboration with Amersham Health, will address
such possibilities.

74

B

Liver
Kidneys

Tumor
Split urine

Figure 2.34.

Bio-distribution of VEGFuo-Peptide 5 or VEGF..0 control

observed by y camera imaging at 120 minutes after injection (MAI). (A)
Image of VEGFno-Peptide 5. (B) Image of VEGFno (no chelator). The
radiolabeled protein is localized to the tumor, urinary tract, liver and
kidneys. Note the asymmetry in the image. No y radiation emanates
from the left thigh (tumor free) of the mouse.
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C h a p t e r 3: C o n c l u s i o n s a n d F u t u r e Perspectives

T h e introduction of unnatural moieties into proteins opens the possibility of
exploiting the orthogonality and selectivity that chemistry has to offer to study

polypeptides in their natural environment. This thesis describes the ligation of

synthetic molecules to target proteins in an intracellular environment, and

the use of semi-synthetic proteins for whole animal studies.

Protein semi-synthesis was first explored in a cellular setting. Specifically, a
methodology was developed to site-specifically modify proteins in living cells. First,
the ANTP PTD peptide was successfully evaluated as a means of introducing in vitro
manipulated peptides into cultured eukaryotic cells. It was shown that ANTP
could translocate up to 70 amino acids, and reliably deliver the L-FLAG
polypeptide for reaction in vivo. A split intein system was then used to perform
protein semi-synthesis in vivo. Protein trans-splicing was chosen because the split

inteins are promiscuous with respect to their flanking sequences,72 are inactive

when expressed individually,87 " 128 152 associate exclusively with their corresponding

partner,109 and, specifically for Ssp DnaE, the fragments have high affinity for each

other.96 Such characteristics allowed for the in vivo ligation of a synthetic FLAG
tag onto four different cytosolic proteins (GFP, DHFR, GST and YFP), and one
integral membrane protein (Opsin), thereby demonstrating that, in principle, any
synthetic molecule - a polypeptide or, minimally, a cysteine derivative bearing any
chemical moiety - can be ligated to a protein of interest inside living cells.
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Figure 3.1.

Principle of semi-synthetic protein trans-splicing at the N -

terminus of proteins. The L and L components of the semi-synthetic
protein trans-splicing methodology developed are interchanged to allow
ligation of chemical moieties at the N-terminus of proteins.
Furthermore, since the reaction is triggered by the addition of one of the
components onto the media of cells already expressing the other component,
temporal control is inherent to the system. Lastly, protein trans-splicing could
permit ligation at the C- or N-terminus of proteins by interchanging of the split
intein components (compare Figure 2.5 with Figure 3.1).

This thesis explored protein trans-splicing as a strategy for the semi-

synthesis of proteins in vivo, however, alternative methodologies could be

developed. Specifically, NCL and EPL both have characteristics that make
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them poteintially suitable for semi-synthesis in living cells.

NCL

is a robust

reaction that can take place under physiological conditions and in the
presence of all the functionalities commonly found in proteins, including free
cysteine sulfhydryls.36 Furthermore, the end product of NCL contains a
native peptide backbone at the point of ligation.36 EPL, with NCL as its
last step,103 inherits these same favorable characteristics. Additionally
modified inteins have been shown to be active in vivo,20 and cells are known
to tolerate thiols needed as co-factors in both NCL and EPL.65 Preliminary
experiments have been conducted to test the feasibility of using NCL and
EPL for the semi-synthesis of protein in living cells (data not shown).
Figure 3.2 illustrates the general methodology for semi-synthesis of
proteins in vivo based on NCL. The protein of interest is expressed in
cultured cells fused at its N-terminus to ubiquitin followed by a cysteine
(Figure 3.2 CD). Co-translational removal of ubiquitin by ubiquitin hydrolase
(naturally present in cells) unmasks the N-terminal cysteine, required for
NCL, within the model protein (Figure 3.2 ©). Then, a synthetic molecule
with an a-thioester is introduced into the cell (by use of PTDs), whereupon it can

react with the available N-terminal cysteine (Figure 3.2 ©), resulting in the ligat
of the probe to the selected protein through a normal peptide bond (Figure 3.2
©). Key to this methodology will be the correct removal of ubiquitin from the
protein of interest, and the stability of the resulting protein with an N-terminal
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cysteine, although, removal of ubiquitin from a polypeptide in m a m m a l i a n cells has
been shown to work efficiently in the Muir laboratory (Hofmann and Muir,
unplublished data). Another issue could be the stability of the synthetic OC-thioester

within the cell; however the latter issue could be by-passed if the reaction were to
take place on the cell surface. This strategy would use a minute reactive tag on

Figure 3.3. Principle of protein semi-synthesis based o n E P L in living cells.
the protein of interest, and therefore have minimal effect on the function and

localization of the protein. Furthermore, the chemical moiety would not have

to be synthesized in tandem to an auxiliary polypeptide (e.g. the split intein

halves) making the system potentially more straightforward to use.
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Figure 3.3

illustrates the general methodology

for semi-synthesis of

protein in vivo based on EPL. The protein of interest is expressed in
cultured cells with a modified GyrA intein fused to its C-terminus (Figure
3.3 ®). Then, a semi-synthetic cysteine derivative is introduced into the cell
using PTDs (Figure 3.3 ©). The cysteine derivative would attack the Os
thioester generated by the intein, displacing the intein and attaching itself to
the protein through a native peptide bond (Figure 3.3 (D). Key to this

Figure 3.2.

Principle of protein semi-synthesis based on N C L in living

cells. Ubiquitin is in brown and the ubiquitin hydrolase is
represented as a pair of scissors. When the ubiquitin is removed an
N-terminal cvsreine is unmasked.
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methodology will be the specificity of the reaction in terms of the incoming
peptide, and the minimization of in vivo cleavage. This strategy could by-pass
some of the solubility and localization problems observed with protein transsplicing, as the modified GyrA intein tends to express well. Furthermore,
and as previously mentioned, the methodology would be more straightforward
because the chemical moiety would not have to be synthesized in tandem to
an auxiliary polypeptide (e.g. the split intein halves). It is important to note
that both NCL and EPL could allow for semi-synthesis on membrane
proteins, both intra and extra-cellularly.
Protein semi-synthesis in vivo could become a powerful tool for the
analysis of proteins within their natural context. Probes, such as
fluorophores, cross-linkers, unnatural amino acids and other sensors can now
be added onto cellular proteins, using protein trans-splicing, in order to study
function. The development of NCL and EPL for use in protein semisynthesis in vivo could further increase the permutations for chemically
modifying proteins, and open new routes for investigating and understanding
polypeptides. Furthermore, all of the methodologies would have inherited
temporal control. Table 3.1 presents some possible applications for semisynthetic protein trans-splicing in vivo.
Ultimately, protein semi-synthesis could become an effective instrument
for whole animal studies. To explore the utility of semi-synthetic proteins as
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tools for biological questions in the context of whole animals, a modular
tandem

ligation method

was

developed.

This

approach

combines

three

building blocks: the protein of interest, a second stage affinity tag, and a
chemical moiety of choice.

Table 3.1. Possible applications for semi-synthetic protein trans-splicing
in vivo.
Protein turn-over could be determined independent of
the half-life of the m R N A

using this methodology.

For example, to determine the turn-over rate of the
Determination of
membrane protein Opsin, a construct comprised of
protein turn-over
Opsin-L could be expressed in mammalian cells and
rate
"pulse" labeled with F L A G tag. T h e time that Opsin
takes to completely turn-over would be determined by
monitoring the disappearance of Opsin-FLAG.
A
Bio-sensor for
membrane
proteins

sodium ion channel could be labeled with a small
molecule that chelates Na* ions and, in doing so,

becomes fluorescent.

Such an approach would allow

direct imaging of Na* transport through a specific
channel.
Post-translational modifications of proteins play a
crucial role in cell biology.

Post-translational
modifications

A

c o m m o n modification

involves the addition or removal of phosphate
groups.

This methodology could allow the addition

of non-hydrolysable phosphate groups to proteins of
interest in an attempt to understand the role of
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these modifications. For example Smad-2, k n o w n to
have two phosphorylation sites at its C-terminus,
could be semi-synthetically modified to produce a
unnatural version of Smad-2 containing two nonhydrolysable phosphate groups.

This would allow to

study the effects of a constitutevily active Smad-2.
T h e breakage of a bond that takes place in protein
splicing can be taken advantage of to create a sitespecific proteolysis tool.

Such a tool would allow to

temporally control the separation of two fused polypeptides inside the cell.

For example, a kinase

inhibitor peptide could be cloned onto the CSite- specific
proteolysis

terminus a kinase of interest (PKA), with L present
in between the two (PKA-L-lnhibitor).

W h e n this

construct would be expressed in mammalian cells the
P K A would be inactive due to the presence of the
peptide inhibitor.

U p o n addition of L, semi-

synthetic protein trans-splicing would remove the
inhibition and P K A could become active.

Such work

in underway in the laboratory.

T h e first and last units are dictated by the experiment at hand, but
the intervening unit can be varied to fit circumstantial needs, such as the
conditions for purification. VEGF was used as a model protein in an
attempt to develop a tumor-imaging agent. A ""Tc chelator was ligated to
the C-terminus of VEGFuo with a 6xHis second stage affinity handle, which
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allowed

recovery of a chemically

homogenous

monomeric

protein.

The

refolded and dimeric semi-synthetic VEGFno-Peptide 5 was shown to be
biologically active and able to target tumors in mice.
This thesis has developed methodologies for the application of
synthetic protein chemistry to in vivo systems. Effective approaches have been
established to study proteins in both cellular and whole animal contexts in
an attempt to provide tools to address the question of lifes' regulation by
proteins.
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C h a p t e r 4 : Materials a n d M e t h o d s .

General Methods.

All amino acid derivatives and resins were purchased from
NovaBiochem (San Diego, CA), Peninsula Laboratories (Belmont, CA) and
Bachem (Torrance, CA). All other chemical reagents were purchased from
Sigma-Aldrich (Milwaukee, WI) or Fisher (Chicago, IL). Restriction enzymes
were purchased from New England Biolabs (Boston, MA). Cell culture
reagents were purchased from Gibco BRL. Fugene transfection reagent was
bought from Boehringer Mannheim. Analytical gradient HPLC was
performed on a Hewlett-Packard 1100 series instrument with detection at 214
and 280 nm. Analytical HPLC was performed on a Vydac C18 column (5
micron, 4.6 x 150 mm) at a flow rate of 1 mL/min. Preparative HPLC
was routinely performed on a Waters DeltaPrep 4000 C18 column (15-20
micron, 50x250 mm) at a flow rate of 30 mL/min. All runs used linear
gradients of 0.1% aqueous TFA (solvent A) vs. 90% acetonitrile plus 0.1%
TFA (solvent B). Mass spectrometric analysis was routinely applied to all
synthetic peptides and components of reaction mixtures. Electrospray mass
spectrometry (ESMS) was performed on a Sciex APL100 single quadrupole
electrospray mass spectrometer. Antibodies used were from Zymed, Sigma
and Clontech. Primers were ordered from IDT or Invitrogen. HeLa, MCF-
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7 and C H O

cells were a generous gift from the Simon laboratory.

HUVEC

cells and their media were purchased from Cell Applications.

Peptide Synthesis.

All peptides were synthesized on a 0.5 mmol scale on a 4methylbenzhydrylamine (MBHA) resin according to the in-situ
neutralization/HBTU activation protocol for Boc SPPS, unless otherwise
noted.124 Following chain assembly, global de-protection and cleavage from
the support was achieved by treatment with HF containing 4% v/v p-cresol,
for 1 hour at 0°C. Following removal of the HF, the crude peptide
products were precipitated and washed with anhydrous cold EtzO before
being dissolved in aqueous acetonitrile (50% B) and lyophilized.

Peptide 1:
H-MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAANCFGCGRQIKI
WFQNRRMKWKKGGDYKDDDDKGK(Rh)G-NH,
The peptide was made by NCL between amino acids 1-39 (Peptide a synthesized with an C-terminal CMhioester) and amino acids 40-70 (Peptide b
- synthesized with an N-terminal cysteine).
The crude peptide a was purified by preparative HPLC using a linear
gradient of 30-40% B over 60 minutes. The purified peptide was
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characterized as the desired product by E S M S [observed mass ( O M ) = 4300.1
±1.2 Da; expected mass (average isotopic mass)(EM) = 4301.5 Da].
Rh was attached to the e-NHa group of Lys30 of peptide b using an
orthogonal (Fmoc/Boc) protection strategy. The crude peptide b was purified
by preparative HPLC using a linear gradient of 20-40% B over 60 minutes.
The purified peptide was characterized as the desired product by ESMS [OM
= 4170.5 ± 1.4 Da; EM = 4172.6 Da].
Peptide a (10 mgr; 2.3 (Imols) was mixed with peptide b (5 mgr; 1.2
Jlmols) in 50 mM Tris/HCl pH 7.5 with 100 mM MESNA and 20% (v/v)
acetonitrile. The reaction was allowed to take place overnight at room
temperature, and then was quenched with acid. The crude mixture was
reduced with TCEP and peptide 1 was purified by preparative HPLC using a
linear gradient of 35-45% B over 60 minutes. 11 mgr of peptide 1 was
obtained. The purified peptide was characterized as the desired product by
ESMS [OM = 8366.3 ± Ll Da; EM = 8366.9 Da].

Peptide 2 (L-FLAG):
H-MVKVIGRRSLGVQRIFDIGLPQDHNFLI^NGAIAAN
CFNDYKDDDDKG-NH,
The crude peptide was purified by preparative HPLC using a linear
gradient of 25-45% B over 60 minutes. 41.7 mgr of peptide 2 was
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obtained.

T h e purified peptide was characterized as the desired product (L

FLAG) by ESMS [OM = 5319.2 ± 1.1 Da; EM = 5322.5 Da].

Ic-FLAG-Rh:
H-MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAAN
CFDYKDDDDK(Rh)G-NH>
Rh was attached to the eNIHz group of Lys47 using an orthogonal
(Fmoc/Boc) protection strategy. The crude peptide was purified by
preparative HPLC using a linear gradient of 30-50% B over 60 minutes.
10.3 mgr of Ic-FLAG-Rh was obtained. The purified peptide was
characterized as the desired product (Ic-FLAG-Rh) by ESMS [OM = 5732 ±
1.6 Da; EM = 5732 Da].

Ic(SR)-FLAG:
Ac-CMVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAAN
C(S-CH2CONHz)FNDYKDDDDKG-NH:
The resin from the Ic-FLAG synthesis was used to couple an extra Nacetylated Cys residue protected on the thiol group with a 9-fluoronylmethyl
(Fm) group. The crude peptide was purified by preparative HPLC using a
linear gradient of 35-55% B over 60 minutes. The purified peptide was
characterized as Ac-Cys(Fm)-Ic-FLAG by ESMS [OM = 5687.3 ± 1.7 Da; EM
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= 5687.7 Da].

T h e peptide was then alkylated in solution by resuspending

it in 5 mL of DMF with 5% DIEA with 10 mM iodoacetamide. The
reaction was allowed to proceed for 15 minutes at room temperature and
500 JlL of IM DTT was then added to quench the un-reacted
iodoacetamide. After 5 minutes at room temperature, piperidine was added
to a final concentration of 20% to deprotect the N-terminal Cys. The
reaction was then quenched with 5 volumes of 20% buffer B and was
purified by preparative HPLC using a linear gradient of 0-70% B over 60
minutes. 3.2 mgr of L(S-R)-FLAG was obtained. The purified peptide was
characterized as the desired product (L(S-R)-FLAG) by ESMS [OM = 5566.2
± 1.7 Da; EM = 5567.6 Da].

ANTP:
H-C(NPyS)RQIKIWFNNRRMKWKKKG-NH2
The crude peptide was purified by preparative HPLC using a linear
gradient of 35-45% B over 60 minutes. 74.4 mgr of ANTP was obtained.
The purified peptide was characterized as the desired product (ANTP) by
ESMS [OM = 2730.0 ± 0.1 Da; EM = 2731.3 Da].

Rh-ANTP:
H-C(NPyS)RQIKIWFNNRRMKWKKK(Rh)G-NH!
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Rh

was attached to the £-NH; group

of Lys16 using an orthogonal

(Fmoc/Boc) protection strategy. The crude peptide was purified by
preparative HPLC using a linear gradient of 20-40% B over 60 minutes.
6.6 mgr of Rh-ANTP was obtained. The purified peptide was characterized
as the desired product (Rh-ANTP) by ESMS [OM = 2842.5 ± 0.5 Da; EM =
2842.9 Da].

Peptide 3:
H-CGRGK(Rh)G-NH2
Rh was attached to the e-NHi group of Lys5 using an orthogonal
(Fmoc/Boc) protection strategy. The crude peptide was purified by
preparative HPLC using a linear gradient of 10-30% B over 60 minutes. 13
mgr of peptide 3 was obtained. The purified peptide was characterized as
the desired product (peptide 3) by ESMS [OM = 987.9 ± 0.3 Da; EM =
988.2 Da].

Coupling of the L-probe to the P T D .
Ic-FLAG, Ic-FLAG-Rh or L(SR)-FLAG was dissolved together with
ANTP or Rh-ANTP in degassed 50 mM Tris/HCl buffer pH 7.5 to a
concentration of 1 mM in each. The peptides were allowed to react for 5
minutes at room temperature and the reaction was then quenched with 10
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volumes

of buffer A

and

purified over preparative

HPLC

using a liner

gradient of 20-40% B over 60 minutes. The purified peptides were
characterized as the desired products by ESMS [ANTP-S-S-Ic-FLAG, OM =
7895.8 ± 0.5 Da, EM = 7895.5 Da; ANTP-S-S-L-FLAG-Rh, OM = 8309.8 ±
1.5 Da, EM = 8309.8 Da; Rh-ANTP-S-S-Ic-FLAG, OM = 8267.2 ± 2.5 Da,
EM = 8265.3 Da; ANTP-S-S-L(SR)-FLAG, OM = 5566.3 ± 1.7 Da, EM =
5568.7 Da].

Peptide 4:
Thial-PHHHHHH-SEt
The peptide was synthesized on a S-propionamide derivatized PEGA
resin on a 0.15 mmol scale. The peptide was simultaneously cleaved from
the resin and de-protected by overnight stirring in 10% aqueous ethanethiol.
The ethanethiol was then removed in vacuo, and the resulting yellow solution
was lyophilized. The crude peptide was purified by preparative HPLC using
a linear gradient of 10-25% B over 60 minutes. The purified peptide was
characterized as the desired product (Peptide 4) by ESMS [OM = 1057 ±0.1

Da; EM = 1056.1 Da].

Peptide 5:
H-CHHHHHH-SN1325-01
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SN1325-01 (12 mgr; 0.0287

m m o l ) and peptide 4 (47 mgr; 0.0431)

were dissolved in 15 mL of buffer containing 200 mM sodium phosphate,
200 mM NaCl, 0.1% Triton X-100, 100 mM MESNA pH 7.2. The
reaction was allowed to proceed for 3 days at room temperature. 5 mL of
IN NaOH was added to bring the pH to 12.5 and hydrolyze remaining CLthioesters. After 3 minutes, 7.5 mL of IM HC1 were added to bring the
pH to 4.5. Methoxylamine-HCl (1.127 grams) was then added and the
deprotection reaction was allowed to take place overnight at room
temperature. The ligation product was purified by preparative HPLC using a
linear gradient of 10-25% B over 60 minutes. The purified peptide was
characterized as the desired product (Peptide 4) by ESMS [OM = 1400.3 ±
0.5 Da; EM = 1401.4 Da].

Expression plasmids.

All plasmids were constructed using standard molecular biology
techniques,123 and they were sequenced to verify correct coding.
pGFP-L: A PCR fragment amplified with IGpr63 and IGpr64, encoding L
with 5 N-terminal extein residues (KFAEY) (using the plasmid reported in 151
as the template) was inserted at the C-terminus of GFP on pEGFPNl
(Clontech) between the BsRG I and Not I restriction sites.
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p6xHis-GFP-L: A

PCR

fragment

amplified

with

IGprl02

and

IGprl03,

encoding 6xhisGFP-L (using pGFP-L as the template) was inserted into
pETlld (Novagene) between the Nhe I and BamH I restriction sites.

pGFP-L(Ala250): Cys250 of pGFP-L was mutated to Ala using Quickchange
Site-Directed Mutagenesis Kit (Stratagene) with IGprlll and IGprll2.

pNl: The sequence of EGFP was removed from pEGFPNl by digestion
with Bsp 120 I and Not I, and the backbone was then re-ligated to make
pNl.

pGST-L: A PCR fragment amplified with IGpr81 and IGpr83, encoding
GST (using pGEX 2T (Amersham Bioscience) as the template) was inserted
into pNl between the Bgl II and EcoR I restriction sites. A PCR
fragment amplified with IGpr84 and IGpr85, encoding L with 5 N-terminal
extein, was then inserted at the C-terminus of GST between the Hind III
and EcoR I restriction sites.

pDHFR-L: A

PCR

fragment amplified with IGpr86 and IGpr87, encoding

6xhisDHFR (using pMT490 as template) was inserted into pNl between the
Bgl II and Nhe I restriction sites. A PCR fragment amplified with IGpr90
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and IGpr91, encoding L with 5 N-terminal extein, was then inserted at the
C-terminus of 6xhisDHFR between the Xma I and Bgl II restriction sites.

pYFP-L-CFP: A PCR fragment amplified with IGpr99 and IGprlOl,
encoding L with 5 N-terminal extein, was inserted at the N-terminus of CFP
on pCFP (Clontech) between the EcoR I and BamH I restriction sites. The
resulting intermediate plasmid was digested with BsiW I and Not I to
removed the L-CFP fragment and inserted it onto the C-terminus of YFP on
pYFPNl (Clontech) between the BsRG I and Not I restriction sites.

pOpsin-GFP-L: A PCR fragment amplified with IGpr75 and IGpr92,
encoding Opsin, was inserted at the N-terminus of GFP on pEGFPNl
between the Sac I and EcoR I restriction sites. Then a PCR fragment
amplified with IGpr63 and IGpr64, encoding L with 5 N-terminal extein
residues (KFAEY) (using the plasmid reported in 151 as the template) was
inserted at the C-terminus of Opsin-GFP between the BsRG I and Not I
restriction sites.

pTnfR-GFP: A

PCR

fragment amplified with IGpr29 and IGpr30, encoding

the trans-membrane domain of TnfR, was inserted at the N-terminus of GFP
on pEGFPNl between the Hind III and EcoR I restriction sites.
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pTnfR-GFP-L:

A

PCR

fragment

amplified

with

IGpr63

and

IGpr64,

encoding L with 5 N-terminal extein residues (KFAEY) (using the plasmid
reported in 151 as the template) was inserted at the C-terminus of TnfR-GFP
between the BsRG I and Not I restriction sites.

pL-GyrA-CBD:

A

PCR

fragment

amplified

with

IGpr65

and

IGpr66,

encoding L with 3 C-terminal extein residues (CFN) (using the plasmid
reported in 151 as template) was inserted at the N-terminus of Gyrase A on
pTXBl (NEB) between the Nde I and Sap I restriction sites.

pVEGFuo-GyrA-CBD: A PCR fragment amplified with RFpr09 and RFprlO,
encoding VEGFuo with four extra C-terminal amino acids (AAAAGG) (using
a hVEGF coding plasmid from Research Genetics as template) was inserted
at the N-terminus of Gyrase A on pTXBl (NEB) between the Nde I and
Sap I restriction sites.

Primers.

IGpr63: CGCGCGTACGGCGGCGGCGGCGGCGGCAAGTTTGCGGAAT
ATTGC
IGpr64: CGCGCGGCGGCCGCTTATTTAATTGTCCCAGCG
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!Gprl02:

CTAGCTAGCATGCACCACCACCACCACCACGGGGTGAGCA

AGGGCGAGG
IGprl03: CGGGATCCGCGGCCGCTTATTTAATTGTCCCAGCGTC
IGprl 1 li GCAAGTTTGCGGAATATGCCCTCAGTTTTGGCACC
IGprl 12: GGTGCCAAAACTGAGGGCATATTCCGCAAACTTGC
!Gpr81: GAAGATCTATGTCCCCTATACTAGG
lGpr83: CGAATTCTCATCAAAGCTTATCCGATTTTGGAGGATGG
IGpr84: GGGAAGCTTAAGTTTGCGGAATATTGCC
!Gpr85: CGAATTCTCATTATTTAATTGTCCCAGCG
lGpr86: GGGGCTAGCATGCATCATCATCATCATCATGTTCGACCATTG
AACTCG
lGpr87: CCCGAGATCTGATTTCTTCTCGTAGACTTCAAAC
IGpr90: CCCCCCGGGAAGTTTGCGGAATATTGCC
!Gpr91: GGGAG ATCTTCATTATTTAATTGTCCCAGCGTC
IGpr99: GGAATTCCGTACGGGAAGTTTGCGGAATATTGCC
IGprlOl:
CGGGATCCCCTCCTCCTCCTCCTCCTTTAATTGTCCCAGCGT
C
IGpr75: CCCGAGCTCATGAACGGTACCGAAGGCCC
IGpr92: GGAATTCGGGCAGGCGCCACTTGGCTGG
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!Gpr29:

CCCAAGCTTGCCGCCACCATGGCCATGGATCAAGCTAGATCA
GC
lGpr30: GGAATTCGTGCAGGGAAGTCCTCTCC
IGpr65: GGGAATTCCATATGGTTAAAGTTATCGG
IGpr66: GGGCCCGTACCGTTAAAACAATTGGCGGC
RFpr09: GGAATTCCATATGGCACCCATGGCAGAAGG
RFprlO: CCCAAGGCGCCGCCGGCGGCGGCGGCTGGTCTGCATTCAAC
ATTTG

Bacterial expression and purification.

6xHisGFP-L: E. coli BL21 (DE3) cells (Invitrogen) were transformed with
p6xhisGFP-L. Expression was carried out in LB media at 37°C. Cells were
grown to an OD5«o™ of 0.8, and protein expression was induced by addition
of isopropyl-P-D-thiogalactopyranoside (IPTG) to a final concentration of 1

mM. After 5 hours the cells were harvested by centrifugation. The cell
pellet was resuspended in bacterial lysis buffer (100 mM Tris/HCl pH 7.5,
500 mM NaCl, 20 mM fi-mercaptoethanol and protease inhibitors (Roche))
and disrupted using a french press. Insoluble material was pelleted by
centrifugation and the supernatant was added onto Ni-NTA agarose beads
(Novagen) previously equilibrated in lysis buffer. After overnight incubation
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at 4 ° C the beads were washed twice with lysis buffer and the protein was
eluded with lysis buffer containing 500 mM imidazole. The eluant was
dialyzed against storage buffer (100 mM Tris/HCl pH 7.5, 500 mM NaCl, 1
mM EDTA and 10 mM DTT), and stored at 4°C.

Ic-GyrA-CBD: E. coli BL21 (DE3) cells were transformed with pIc-GyrA-CBD.
Expression was carried out in LB media at 25 °C. Cells were grown to an
OD59o»„ of 0.8, and protein expression was induced addition of IPTG to a
final concentration of 1 mM. After 5 hours the cells were harvested by
centrifugation. The cell pellet was resuspended in bacterial lysis buffer (50
mM Tris/HCl pH 7.5, 200 mM NaCl, 5% glycerol, 0.1 mM EDTA and
protease inhibitors) and disrupted using a french press. Insoluble material
was pelleted by centrifugation and the supernatant was added onto chitin
beads (NEB) previously equilibrated in lysis buffer. After overnight
incubation at 4°C the beads were washed twice with lysis buffer and stored
at 4°C.

V E G F u ^ G y r A - C B D : E. coli B L 2 1 (DE3) cells were transformed with p V E G F ™ GyrA-CBD. Expression was carried out in LB media at 37 "C. Cells were
grown to an ODsw™ of 0.8, and protein expression was induced by addition
of IPTG to a final concentration of 1 mM. After 5 hours the cells were
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harvested by centrifugation.

T h e cell pellet was resuspended in bacterial lysis

buffer (25 mM sodium phosphate pH 7.0, 250 mM NaCl, 0.1 mM EDTA,
5% glycerol, and protease inhibitors) and disrupted using a french press.
Insoluble material was pelleted by centrifugation. The pellet was washed
with 2 M urea in lysis buffer, and insoluble material was pelleted by
centrifugation. The pellet was resuspended in 200 mM sodium phosphate pH
7.2 and 8 M urea and insoluble material removed by centrifugation. The
supernatant was dialyzed for 24 hours against 50 mM Tris/HCl pH 7.5, 200
mM NaCl, 1 mM EDTA and 0.1% Triton X-100 in a Spectra Pore dialysis
bag with a 10,000 Da molecular weight cutoff. The dialyzed solution was
centrifuged to remove insoluble components, and was then loaded onto a
chitin column (NEB) previously equilibrated with 200 mM sodium phosphate
pH 7.2, 200 mM NaCl, 0.1% triton X-100. After overnight incubation at
4°C, the column was washed with buffer containing 200 mM sodium
phosphate pH 7.2, 200 mM NaCl, 0.1% triton X-100 and stored at 4°C.

In vitro reactions.

Semi-synthetic protein trans-splicing: The bacterially expressed 6xHisGFP-L in
100 mM Tris/HCl pH 7.5, 500 mM NaCl, 1 mM EDTA and 10 mM DTT
was added to Ic-FLAG to obtain a final concentration of the peptide of 100
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rltM. T h e mixture was allowed to react at room temperature for 5 hours and
was then analyzed by SDS-PAGE gel (12%) and by an anti-FLAG blot.

EPL of Ic-GyrA-CBD with peptide 3: An aliquot of the bead slurry containing
immobilized Ic-GyrA-CBD was incubated overnight with 1 mL of peptide 3
(1 mM) in PBS with 100 mM MESNA at room temperature. The reaction
was monitored by SDS-PAGE. The supernatant was removed and the beads
were washed with 8 M urea. The eluant was injected into the analytical
HPLC to analyze the reaction, and to confirm product formation by ESMS
[Ic-Peptide 3: OM = 5298.3 ± 2.0 Da; EM = 5299.7 Da].

E P L between V E G F u o - G y r A - C B D and SN1400-01:

VEGFuo-GyrA-CBD

chitin beads (30 mL) were treated in 50 mL ligation buffer (200 mM
sodium phosphate pH 7.2, 200 mM NaCl, 0.1% triton X-100) with 100 mM
MESNA and 2% (v/v) ethanethiol in the presence of SN 1400-01 peptide (10
mgr; 22.4 .Umols) and rocked for 2 days at room temperature. The
column was drained, washed with ligation buffer, and the ligation product
was eluted by washing the column with a buffer containing 8 M urea, 200
mM sodium phosphate, 20 mM DTT, pH 7.2. The urea solution was then
dialyzed against 20 mM Tris/HCl pH 8.0, 200 mM NaCl. A mixture of
the ligation products, VEGFuo-SN 1400-01 and VEGFuo (hydrolysis product)
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were purified by preparative H P L C using a linear gradient of 3 2 - 4 7 % B over
60 minutes. The purified proteins were characterized by ESMS [VEGFuoSN1400-01 OM = 12934.3 ± 1.4 Da; EM = 12930.6 Da and VEGFuo OM =
12506.1 ± 1.4 Da; EM = 12502.3 Da].

EPL between VEGF„o-GyrA-CBD and peptide 5: VEGFuo-GyrA-CBD chitin
beads were treated with 2% ethanethiol in ligation buffer for 2 days. The
VEGFuo a-thioester was eluted by overnight treatment with 8 M Urea, 200
mM sodium phosphate, pH 7.2 with 2% ethanethiol, and purified by
preparative HPLC using a linear gradient of 40-55% B over 60 minutes.
VEGFuo ethyl thioester (5 mgr; 0.4 Jlmols) were then dissolved in 6 M
guanidine, 200 mM sodium phosphate pH 7.2, 200 mM sodium chloride,
2% ethanethiol and 100 mM MESNA in the presence of peptide 5 (5 mgr;
11.9 Jlmols). The reaction was allowed to take place overnight at room
temperature. The ligation mixture was purified by size-exclusion
chromatography on a Zorbax GF-450 column using a flow rate of 5 mL/min
and a running buffer containing 6 M guanidine, 200 mM NaCl, 200 mM
sodium phosphate pH 7.2, 20 mM 2-mercaptoethanol, and 0.1 mg/mL BSA.
The fraction containing VEGFuo-Peptide 5 was then further purified by NiNTA chromatography over a Hi-Trap Affinity column (Pharmacia), on a
Pharmacia FPLC system, at a flow rate of 5 mL/min using 6 M guanidine,
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200 m M

sodium phosphate, 500 m M

NaCl, 20 m M

2-mercaptoethanol p H

7.4 as loading buffer, and an identical buffer with 500 mM imidazole as the
eluting buffer. Purified VEGFuo-Peptide 5 was oxidatively refolded according
to literature protocols30 by dialyzing against 20 mM Tris/HCl pH 8.0, 400
mM sodium chloride, 1 mM cysteine. Dimeric VEGFuo-Peptide 5 was then
separated from monomeric and other oligomeric species by gel filtration
chromatography on a Zorbax GF-250 column using a flow rate of 5 mL/min
and PBS as the running buffer.

Fluorescence Microscopy.

Live cell imaging: HeLa were grown in DMEM+ 10% fetal bovine serum
(FBS) media at 37 °C with 5% COz in a microscopy chamber. Peptide 1
was added to a final concentration of 1 nM. After 30 minutes incubation,
the cells were washed with Hanks' balanced salt solution (HBSS) and imaged
live by fluorescence microscopy on an Axiovert 200 M inverted microscope.
A TxRd filter (Chroma) was used to image the Rh signal, and the data was
analyzed using MetaMorph (Universal Imaging).

Fixed cell imaging for peptide localization: HeLa cells were grown in DMEM
+ 10% FBS media at 37 °C with 5% COz, on #1.5 glass cover slips (Fisher).
Before adding the peptides (ANTP-S-S-Ic-FLAG-Rh or Rh-ANTP-S-S-Ic-FLAG),
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the cells were washed

twice with PBS, and then fresh media was

added

containing the peptides at a concentration of 2 nM. After 30 minutes of
incubation, the cells were fixed with 3.7% formaldehyde, followed by BSA
blocking and nucleic acid staining with Hoechst. The cover slips were
inverted onto a glass slide and sealed with nail polish before fluorescence
microscopy analysis. A DAPI or a TxRd filter (Chroma) was used to
visualize the signals from Hoechst or Rh, respectively. The data was
analyzed using MetaMorph.

Fixed cell imaging for protein localization: HeLa or MCF-7 cells were grown
in DMEM + 10% FBS media at 37 °C with 5% C02, on #1.5 glass cover
slips, and transiently transfected with the desired plasmids using Fugene.
After 24 hours of expression the cells were washed twice with PBS and fixed
with 3.7% formaldehyde, followed by BSA blocking and nucleic acid staining
with Hoechst. The cover slips were inverted onto a glass slide and sealed
with nail polish before fluorescence microscopy analysis. A FITC filter
(Chroma) was used to image the GFP signal, and the data was analyzed
using MetaMorph.
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Western Analysis of pGFP-L .

CHO cells, grown in F12-HAM + 10% FBS media at 37 °C with 5%
CO2, were transiently transfected with pGFP-L using Fugene. After 24 hours
of expression the cells were washed twice with PBS and harvested. The cell
pellet was resuspended in SDS sample buffer and loaded onto an SDS-PAGE
gel (12%) for blotting against GFP.

Semisynthetic protein trans-splicing.

10 cm plates of CHO cells were transfected with a mammalian vector
based on pEGFP-Nl (Clontech) encoding the L fusion protein (GFP-L, GFPL(Ala2»), GST-L, DHFR-L, YFP-L-CFP or Opsin-GFP-L). After 24 hours of
transient expression, the cells were washed twice with 10 mL of PBS and
fresh media (2.5 mL) containing 0.5% DMSO or 0.5% DMSO with the
peptide (ANTP-S-S-Ic-FLAG or ANTP-S-S-L(SR)-FLAG) to a final concentration
of 100 (iM was added. The cells were then incubated for three hours,

washed twice with 10 mL of PBS and harvested. The cell pellet was
resuspended in 1 mL of lysis buffer: PBS containing 1% (w/v)
docecylmaltoside (DM), 10 mM iodoacetamide, 2 mM N-ethyl-maleamide and
protease inhibitors (Roche). All subsequent manipulations were performed at
4°C. Lysis was carried out for 1 hour after which insoluble material was
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removed by micro-centrifugation at 16,000g for 30 minutes. T h e supernatant
was pre-cleared for immuno-precipitation by incubation with 50 [iL of
Protein-A immobilized on sepharose CL-4B (Sigma) or mouse IgG agarose
(Sigma) for 1 hour. The beads were then removed by micro-centrifugation
at 16,000g for 5 minutes and the supernatant added onto 50 JlL of antiFLAG-Protein-A sepharose, anti-GFP-Protein-A sepharose or anti-FLAG M2agarose affinity gel (Sigma) pre-blocked with bovine albumin (BSA). Immunoprecipitation was allowed to take place overnight and the beads were then
washed three times for 5 minutes with 1 mL of PBS before being
resuspended in SDS sample buffer for analysis by western blotting.

Endothelial Cell Proliferation Assay.

A plate of HUVEC primary cultures (Cell Applications) was grown to
confluence over 4 days using endothelial cell growth media (Cell
Applications). VEGF samples were reconstituted by dissolving or diluting the
samples to generate a 10 \lg/mL stock in PBS with 1 mg/mL BSA (Sigma).
These stocks were diluted into assay medium (medium 199 with 10 mM
HEPES, 10% FBS, 100 units/mL penicillin, 100 |lg/mL streptomycin) at

various concentrations, and 75 \lL of each dilution was plated in triplicate
in a 96-well plate. 50 |lL of a solution of IO5 cells/mL in assay medium
was then added to each well. The cells were allowed to grow for 48 hours
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under 5 %

C O , at 3 7 " C

degrees.

10 |lL of a 50 (iCi/mL stock of 'H-

Thymidine (NEN) was added to each well, and the cells were allowed to
grow for an additional 24 hours. The cells were dissociated with trypsin,
and counted in a scintillation counter. The data were fitted to a sigmoidal
dose response curve using Prism 3.0 (Graphpad Software), using the following
equation:

E = Basal+E™*~Basal/
Cj Dasat +

^^0(LogEC50-Log[A?« )

where E denotes effect, [A] the VEGF concentration, nH the midpoint

slope, EC50 the midpoint location parameter, and E™. and Basal the

upper and lower asymptotes, respectively.
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Academic Course W o r k

Transmission genetics.
Introduction to protein function.
Development of the nervous system.
Mammalian genetics.
Protein folding and structure prediction.
Gene expression.
Advanced organic chemistry.
Laboratory Rotations

September 1997 - December 1997: Dr. Ali Hemmati Brivalauo
January 1998 - April 1998: Dr. John Kuryain
May 1998 - March 1999: Dr. Titia de Lange
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D.P., Muir, T.W., (2001) ]. Mol. Biol, 308 p. 1045.
Giriat, I., Muir, T.W., Perler, F.B., (2001) Genetic Engineering, 23 p.171.
Stanger, H.E., Syud, F.A., Espinosa, J.F., Giriat, I., Muir, T., Gellman, S.H.,
(2001) PNAS, 98 p. 12015.
Giriat, I.; Muir, T.W. (2003) submitted to JACS.
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